Journal articles on the topic 'Fishers Singapore'
To see the other types of publications on this topic, follow the link: Fishers Singapore.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Fishers Singapore.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Hazera, Eduardo, Jan De Wolf, Cristiano Lanzano, Diana Mata-Codesal, Priya Bose, Daria Tukina, Thomas Bierschenk, Mattias Borg Rasmussen, Jesko Schmoller, and Bhargabi Das. "Book Reviews." Social Anthropology/Anthropologie Sociale 30, no. 4 (December 1, 2022): 149–65. http://dx.doi.org/10.3167/saas.2022.300411.
Full textAbstract:
Muecke, Stephen and Paddy Roe. 2020. The Children's Country: Creation of a Goolarabooloo Future in North-West Australia. New York: Rowman & Littlefield. 252 pp. Hb.: US$44.95. ISBN: 9781786616487. Donzelli, Aurora. 2020. One or Two Words: Language and Politics in the Toraja Highlands of Indonesia. Singapore: NUS Press. xx +289 pp. Hb.: S$56.00. ISBN: 978-981-3251-14-4. D'Angelo, Lorenzo. 2019. Diamanti. Pratiche e stereotipi dell'estrazione mineraria in Sierra Leone [Diamonds. Mineral Practices and Stereotypes in Sierra Leone]. Milan: Meltemi. 180 pp. Pb: €16.00. ISBN: 9788883539732. Jackson, Michael D. 2020. Quandaries of Belonging: Notes on Home, from Abroad. London: Union Bridge Books. 187 pp. Kindle Edition: £23.75. Sur, Malini. 2021. Jungle Passports: Fences, Mobility, and Citizenship at the Northeast India–Bangladesh Border. Philadelphia, PA: University of Pennsylvania Press. 227 pp. Pb.: US$24.00. ISBN: 978-0-8122-5279-8. Montesi, Laura and Melania Calestani (eds.) 2021. Managing Chronicity in Unequal States: Ethnographic Perspectives on Caring. London: UCL Press. 272 pp. Hb.: £40.00. ISBN: 9781800080300. Koch, Insa Lee. 2018. Personalizing the State. An Anthropology of Law, Politics and Welfare in Austerity Britain. 290 pp. Hb.: £70.00. Oxford: Oxford University Press. ISBN: 9780198807513. Stensrud, Astrid B. 2021. Watershed Politics and Climate Change in Peru. London: Pluto Press. 240 pp. Hb.: US$54.74. ISBN: 9780745340203. Li, Darryl. 2020. The Universal Enemy. Jihad, Empire, and the Challenge of Solidarity. Stanford, CA: Stanford University Press. 384 pp. Pb.: US$30.00. ISBN: 9781503610873. Roszko, Edyta. 2020. Fishers, Monks and Cadres: Navigating State, Religion and the South China Sea in Central Vietnam. Copenhagen: NIAS Press. 288 pp. Hb.: £65.00. ISBN: 9788776942861.
2
Boomgaard, Peter, R. H. Barnes, Sini Cedercreutz, Janet Carsten, Freek Colombijn, Brenda S. A. Yeoh, Robert Cribb, et al. "Book Reviews." Bijdragen tot de taal-, land- en volkenkunde / Journal of the Humanities and Social Sciences of Southeast Asia 154, no. 3 (1998): 478–517. http://dx.doi.org/10.1163/22134379-90003893.
Full textAbstract:
- Peter Boomgaard, R.H. Barnes, Sea hunters of Indonesia; Fishers and weavers of Lamalera. Oxford: Clarendon Press, 1996, xxii + 467 pp. - Sini Cedercreutz, Janet Carsten, The heat of the earth; The process of kinship in a Malay fishing community. Oxford: Clarendon Press, 1997, xv + 314 pp., plates, figures, maps, bibliography, index. - Freek Colombijn, Brenda S.A. Yeoh, Contesting space; Power relations and the urban built environment in colonial Singapore. Kuala Lumpur, Oxford, Singapore and New York: Oxford University Press, 1996, xxiii + 351 pp., tables, figures, plates, index. - Robert Cribb, H.A.J. Klooster, Bibliography of the Indonesian Revolution; Publications from 1942 to 1994. Leiden: KITLV Press, 1997, viii + 666 pp., indices. [Bibliographical Series 21.] - Gavin W. Jones, Sharifah Zaleha Syed Hassan, Managing marital disputes in Malaysia; Islamic mediators and conflict resolution in the Syariah courts. Richmond, Surrey: Curzon Press, 1997, 252 pp., Sven Cederroth (eds.) - Bernice de Jong Boers, G.J. Schutte, State and trade in the Indonesian archipelago. Leiden: KITLV Press, 1994, viii + 199 pp. [Working Papers 13.] - Nico Kaptein, Greg Barton, Nahdlatul Ulama; Traditional Islam and modernity in Indonesia. Clayton, Victoria: Monash Asia Institute, 1996, xvii - 293 pp., Greg Fealy (eds.) - Gerrit Knaap, J.E. Schooneveld-Oosterling, Generale Missiven van Gouverneurs-Generaal en Raden aan Heren XVII der Verenigde Oostindische Compagnie. Vol. XI. Den Haag: Instituut voor Nederlandse Geschiedenis. [Rijks Geschiedkundige Publicatiën, Grote Serie 232], 1997, xii + 949 pp. - Niels Mulder, Unni Wikan, Managing turbulent hearts; A Balinese formula for living. Chicago, London: The University of Chicago Press, 1990, xxvi + 343 pp. - Sandra Niessen, Janet Rodenburg, In the shadow of migration; Rural women and their households in North Tapanuli, Indonesia. Leiden: KITLV Press, vii + 214 pp. [Verhandelingen 174.] - Dianne W.J.H. van Oosterhout, Roy Ellen, The cultural relations of classification; An analysis of Nuaulu animal categories from central Seram. Cambridge University Press 1993, 315 pp. [Cambridge Studies in Social and Cultural Anthropology 91] - Anton Ploeg, Douglas James Hayward, Vernacular Christianity among the Mulia Dani; An ethnography of religious belief among the western Dani of Irian Jaya. Lanham, Maryland: American Society of Missiology and University Press of America, 1997, ix + 329 pp. - M.J.C. Schouten, Laura Summers, Gender and the sexes in the Indonesian Archipelago. (complete issue of Indonesia Circle 67 (November 1995), pp. 165-359.), William Wilder (eds.) - Bernard Sellato, Y.C. Thambun Anyang, Daya Taman Kalimantan; Suatu studi etnografis organisasi sosial dan kekerabatan dengan pendekatan antropologi hukum. Nijmegen: Nijmegen University Press, 1996, xii + 268 pp. - Gerard Termorshuizen, E.M. Beekman, Troubled pleasures; Dutch colonial literature from the East Indies, 1600-1950. Oxford: Clarendon Press, 1996, 654 pp. - Jeroen Touwen, J.Th. Lindblad, Historical foundations of a national economy in Indonesia, 1890s-1990s. Amsterdam: North Holland, 1996, iv + 427 pp. [KNAW Verhandelingen, Afdeling Letterkunde, Nieuw Reeks 167.]
3
NG, HEOK HEE, and HEOK HUI TAN. "AN ANNOTATED CHECKLIST OF THE NON-NATIVE FRESHWATER FISH SPECIES IN THE RESERVOIRS OF SINGAPORE." COSMOS 06, no. 01 (August 2010): 95–116. http://dx.doi.org/10.1142/s0219607710000504.
Full textAbstract:
We have recorded 54 species of non-native or alien freshwater fishes from 14 of the 15 reservoirs in Singapore. 31 of these species are established and breeding in the reservoirs. Three species (Mystus wolffii, Amphilophus citrinellum, and Satanoperca jurupari) represent new alien records for Singapore.
4
LEE, KING FUEI. "AN EMPIRICAL STUDY OF THE FISHER EFFECT AND THE DYNAMIC RELATION BETWEEN NOMINAL INTEREST RATE AND INFLATION IN SINGAPORE." Singapore Economic Review 54, no. 01 (April 2009): 75–88. http://dx.doi.org/10.1142/s0217590809003173.
Full textAbstract:
The Fisher Effect postulated that real interest rate is constant, and that nominal interest rate and expected inflation move one-for-one together. This paper employs Johansen's method to investigate for the existence of a long-run Fisher effect in the Singapore economy over the period 1976 to 2006, and finds evidence of a positive relationship between nominal interest rate and inflation rate while rejecting the notion of a full Fisher Effect. The dynamic relationship between nominal interest rate and inflation rate is also examined from the error-correction models derived, and the analysis is extended to investigate the impulse response functions of inflation and nominal interest rates where we discover the presence of the Price Puzzle in the Singapore market.
5
Liem, Gregory Arief D., Andrew J. Martin, Elizabeth Nair, Allan B. I. Bernardo, and Paulus Hidajat Prasetya. "Cultural Factors Relevant to Secondary School Students in Australia, Singapore, the Philippines and Indonesia: Relative Differences and Congruencies." Australian Journal of Guidance and Counselling 19, no. 2 (December 1, 2009): 161–78. http://dx.doi.org/10.1375/ajgc.19.2.161.
Full textAbstract:
AbstractWaldrip and Fisher (2000) proposed seven culturally relevant factors that are salient in the educational setting (gender equity, collaboration, competition, deference, modelling, teacher authority, congruence). In relation to these factors, the present study examined differences and congruencies in factor structure (i.e., differences of kind) and mean scores (i.e., differences of degree) among secondary school students in Australia, Singapore, the Philippines and Indonesia. The Cultural Learning Environment Questionnaire (CLEQ; Waldrip & Fisher, 2000) was administered to 920 students (n= 230 for each country, with boys and girls equally represented; mean age = 16 years). Factor analyses showed congruencies across the four samples on five factors. Interestingly, items pertaining to students' deference to and modelling of teachers and peers grouped into one factor for the Australian sample, but separated into two factors (peers and teacher) for the South-East Asian samples. In terms of mean scores on each factor, Australian students were higher than the Singaporean, Filipino and Indonesian students in their inclination to challenge or disagree with the teacher. On the other hand, the three groups of South-East Asian students scored higher than the Australian students in their preferences for collaboration and conformity in the classroom. Implications for counselling relevant to multicultural classroom and school contexts were discussed.
6
Shimizu, Hiroshi. "The Japanese Fisheries Based in Singapore, 1892–1945." Journal of Southeast Asian Studies 28, no. 2 (September 1997): 324–44. http://dx.doi.org/10.1017/s002246340001448x.
Full textAbstract:
This paper examines the main factors behind the rise and decline of the Japanese fisheries based in Singapore before the Pacific War, and shows that, as the fisheries contributed greatly to the Singapore economy, they did not constitute a foreign economic enclave in the British colony. It also describes how the Japanese and local fishermen conducted fisheries during the period from 1942 to 1945, and argues that the legacy of the Japanese fisheries outlived the Japanese occupation.
7
Clark-Shen, Naomi, Byrappa Venkatesh, Christina Choy Pei Pei, Kathy Xu, and Gavin J. P. Naylor. "Not yet extinct: Rhynchobatus cooki is found after being unseen for over 20 years." Pacific Conservation Biology 26, no. 3 (2020): 308. http://dx.doi.org/10.1071/pc19027.
Full textAbstract:
In May 2019 a female specimen of Rhynchobatus cooki was found at Jurong Fishery Port in Singapore. The specimen had been imported from Indonesia. The species had not been seen for over 20 years, and this discovery gives hope that Rhynchobatus cooki is not yet extinct.
8
Chan, Joleen, Yiwen Zeng, and Darren C. J. Yeo. "Invasive species trait-based risk assessment for non-native freshwater fishes in a tropical city basin in Southeast Asia." PLOS ONE 16, no. 3 (March 16, 2021): e0248480. http://dx.doi.org/10.1371/journal.pone.0248480.
Full textAbstract:
Biological invasions have created detrimental impacts in freshwater ecosystems. As non-native freshwater species include economically beneficial, but also harmful, species, trait-based risk assessments can be used to identify and prevent the import of potentially invasive species. Freshwater fishes are one of the most evaluated freshwater taxa to date. However, such assessments have mostly been done in sub-temperate to temperate regions, with a general lack of such research in the tropics. In view of this knowledge gap, this study aims to determine if a different set of traits are associated with successful establishment of non-native fishes within the tropics. In tropical Southeast Asia, Singapore represents a suitable model site to perform an invasive species trait-based risk assessment for the tropical region given its susceptibility to the introduction and establishment of non-native freshwater fishes and lack of stringent fish import regulation. A quantitative trait-based risk assessment was performed using random forest to determine the relative importance of species attributes associated with the successful establishment of introduced freshwater fishes in Singapore. Species having a match in climate, prior invasion success, lower absolute fecundity, higher trophic level, and involvement in the aquarium trade were found to have higher establishment likelihood (as opposed to native distributional range and maximum size being among the commonly identified predictors in subtropical/temperate trait-based risk assessments). To minimize invasive risk, incoming freshwater fishes could be screened in future for such traits, allowing lists of prohibited or regulated species to be updated. The findings could also potentially benefit the development of invasive species action plans and inform management decisions in the Southeast Asian region. Considering a geographical bias in terms of having relatively less documentation of biological invasions in the tropics, particularly Asia, this study highlights the need to perform more of such risk assessments in other parts of the tropics.
9
Clark-Shen, Naomi, Kathy Xu Tingting, Madhu Rao, Shannon Cosentino-Roush, Rajkumar Sandrasegeren, Anya R. Gajanur, Demian D. Chapman, et al. "The sharks and rays at Singapore’s fishery ports." Fisheries Research 235 (March 2021): 105805. http://dx.doi.org/10.1016/j.fishres.2020.105805.
Full text
10
Hanjavanit, Chutima, Hiroki Suda, and Kishio Hatai. "Mycotic granulomatosis found in two species of ornamental fishes imported from Singapore." Mycoscience 38, no. 4 (December 1997): 433–36. http://dx.doi.org/10.1007/bf02461684.
Full text
11
Kwik, Jeffrey, Zi Yi Kho, Boon Shan Quek, Heok Hui Tan, and Darren Yeo. "Urban stormwater ponds in Singapore: potential pathways for spread of alien freshwater fishes." BioInvasions Records 2, no. 3 (September 2013): 239–45. http://dx.doi.org/10.3391/bir.2013.2.3.11.
Full text
12
Hajisamae, S., L. M. Chou, and S. Ibrahim. "Feeding habits and trophic relationships of fishes utilizing an impacted coastal habitat, Singapore." Hydrobiologia 520, no. 1-3 (June 2004): 61–71. http://dx.doi.org/10.1023/b:hydr.0000027727.90956.a9.
Full text
13
Tan, Denise, Clarinda Sutanto, Jia Wen Xanthe Lin, Kim-Anne Lê, and Jung Eun Kim. "Carbohydrate Quality of a Middle-aged and Older Population in Singapore and Its Association with Cardiometabolic Health." Current Developments in Nutrition 5, Supplement_2 (June 2021): 53. http://dx.doi.org/10.1093/cdn/nzab033_053.
Full textAbstract:
Abstract Objectives Carbohydrate quality plays a key role in cardiometabolic health, though this has not been well investigated in Asian populations. This study aimed to assess the carbohydrate quality of middle-aged and older adults in Singapore, and its association with various cardiometabolic health-related markers. Methods A secondary data analysis of a cross-sectional study consisting of 104 adults (59 ± 6 years, mean ± SD) was conducted. Carbohydrate quality was evaluated by their adherence to: (i) Singapore recommended daily allowance (RDA) for dietary fiber intake, (ii) Singapore recommended daily whole grain intake, (iii) World Health Organization free sugars limit and (iv) the balanced carbohydrate metrics (BCM). The BCM was reflected by a ratio of at least 1g of fiber per 10g of carbohydrates (10:1, simple ratio), or variations including free sugars criteria. Food intake was collected using 3-day food record. Measurements of cardiometabolic health-related markers were body mass index, waist circumference, blood pressure, blood lipid-lipoprotein markers (total, low-density lipoprotein and high-density lipoprotein cholesterol and triglycerides) and glucose and 10-year risk to coronary heart disease. The association between dietary carbohydrate quality and cardiometabolic health-related markers, as well as associations amongst the 4 measures of carbohydrate quality were evaluated using Fisher's exact test. Results 36%, 20%, 87% and 34% of the population met the fiber RDA, whole grain recommendation, free sugars limit and BCM respectively. A significant association in adherence to each measure of carbohydrate quality was found across all 4 measures (P < 0.05), except for between the whole grain recommendation and free sugars limit. The simple ratio was associated with a lower systolic blood pressure (P = 0.04) while no association was observed with other cardiometabolic health-related markers. Conclusions Consuming a diet adhering to the simple ratio of at least 1g of fiber for every 10g of carbohydrates may improve blood pressure and subsequently lower cardiometabolic disease risk. Funding Sources National University of Singapore, Singapore Economic Development Board and Société des Produits Nestlé SA
14
Boršič, Darja, and Jani Bekő. "Purchasing power parity in ASEAN+3: an application of panel unit root tests." Croatian Review of Economic, Business and Social Statistics 4, no. 1 (June 1, 2018): 42–52. http://dx.doi.org/10.2478/crebss-2018-0004.
Full textAbstract:
Abstract The paper assesses the existence of purchasing power parity (PPP) in ASEAN+3 economies taking into account EUR and USD as reference currencies. The research refers to the period from January 2000 to June 2017 and there are three points of view: we tested the period as a whole and then the pre-crisis period and the postcrisis period regarding the structural break due to the economic crisis. The evaluated economies include Brunei, Cambodia, China, Indonesia, Japan, Korea, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam. A range of panel unit root tests are applied, covering the Levin, Lin and Chu test, the Breitung test, the Im, Pesaran and Shin test, the ADF-Fisher test and the PP-Fisher test. In cases where the unit root is rejected, the validity of PPP is confirmed. However, our results are ambiguous and depend on the selection of the base currency, the time period observed and on the choice of the methodology.
15
Azis Husen. "Pemasaran Ikan Tuna (Thunnus sp) di Pelabuhan Perikanan Nusantara (PPN) Kota Ternate." ABDIKAN: Jurnal Pengabdian Masyarakat Bidang Sains dan Teknologi 1, no. 2 (May 30, 2022): 128–33. http://dx.doi.org/10.55123/abdikan.v1i2.254.
Full textAbstract:
The Ternate Archipelago Fishery has a strategic role in development of fisheries and marine affairs, namely as a center for marine fisheries activities.A properly functioning Nusantara Ternate Fishery will be a beneficial point between economic marketing activities at sea and economic marketing activities on land.The purpose of this research is to know the marketing management method of tuna fish at the Ternate Archipelago Fisheries.This research was conducted at the Ternate Archipelago Fishery in Bastiong Village, South Ternate City. The method of data collection was using secondary and primary data.Marketing of tuna exports was 621,951 (kg), in 2018 tuna exports were 540,450 (kg), in 2019 the number of tuna exports was 268,384 (kg), in 2020 tuna exports were 447,550 (kg) and in 2021 PPN Ternate carried out exports 589,767 (kg). Marketing exports of tuna from Ternate, North Maluku directly to Singapore, Vietnam while the aims of export destinations are Bitung, Makassar, Surabaya, Jakarta and Batam. The activity of the fishing business industry is increasing because during the Covid-19 pandemic in 2019-2020 tuna exports experienced a very significant decline.The marketing of tuna for PPN Ternate nationally and internationally is very promising for development, so the marketing strategy is needed to be implemented, including improving facilities and infrastructure, making technological efforts for the fishing boat and fishing gear.
16
Heng, Wee Ling, Thi Thu Ha Truong, Irena WY Tham, Jialin Yick, Inn Yi Chiang, and Tracy SH Seck. "Psychosocial Factors, Knowledge and Attitudes Influencing Skin and Heart Valve Donation among Healthcare Professionals in Singapore." Annals of the Academy of Medicine, Singapore 45, no. 8 (August 15, 2016): 338–50. http://dx.doi.org/10.47102/annals-acadmedsg.v45n8p338.
Full textAbstract:
Introduction: In Singapore, tissue donation is covered under the Medical (Therapy, Education and Research) Act. The objective of this study is to review the demographic and psychosocial factors, which may cause hesitation/unwillingness amongst healthcare professionals towards tissue donation. Materials and Methods: A survey comprising 18-items was conducted at the Singapore General Hospital and National Heart Centre Singapore. A total of 521 individuals participated in the survey. Descriptive statistics were performed for the demographic profiles of participants, the factors leading to the support of tissue donation, reasons for hesitation/reluctance to donate tissue and motivating factors to discuss tissue donation with next-of-kin. Pearson’s chi-square and Fisher’s exact tests were employed to assess possible association between various factors and support towards tissue donation. Analyses were performed using Statistical Package for Social Sciences V.21.0 software. Results: A total of 64.9% of participants had heard about skin donation; 48.9% had heard about heart valve donation; 4.5% were tissue pledgers. The primary reason for pro-donation was the altruism of “improving someone’s quality of life”. However, a majority stated they “can decide this in the later part of life” as their main reason for hesitation; 82.3% were willing to discuss their tissue donation wish with next-of-kin, while 53.1% were likely to make the decision of donation on behalf of their deceased next-of-kin. Conclusion: Results highlighted important psychosocial and professional factors that influence the hesitation/reluctance towards donation. Hence, there is a need to re-strategise educational efforts in accordance with the target audiences and address specific misconceptions and concerns. Key words: Heart valve banking, Tissue donation, Skin allografts, Skin banking
17
Pradianti, Oryssa Sathalica, Winiati Pudji Rahayu, and Ratih Dewanti Hariyadi. "Kajian Kesesuaian Standar Cemaran Kimia (Logam Berat dan PAH) pada Produk Perikanan di Indonesia dengan Standar Negara Lain dan Codex." Jurnal Pascapanen dan Bioteknologi Kelautan dan Perikanan 14, no. 1 (June 28, 2019): 45. http://dx.doi.org/10.15578/jpbkp.v14i1.560.
Full textAbstract:
AbstrakPangan dapat terkontaminasi oleh cemaran kimia karena penanganan dan pengolahan pangan yang tidak sesuai. Tujuan dari penelitian ini adalah 1) mengidentifikasi mayoritas penyebab penolakan produk perikanan Indonesia, 2) menelaah standar cemaran kimia pada produk perikanan, khususnya logam berat yang ada di Indonesia, Codex Alimentariurs Commision (CAC) dan negara-negara lain, serta 3) memberikan rekomendasi bagi pemerintah selaku regulator dalam proses perumusan suatu standar. Dokumen standar cemaran kimia pada produk perikanan dikumpulkan dari dokumen/peraturan yang dikeluarkan oleh Badan Pengawasan Obat dan Makanan (BPOM), Badan Standardisasi Nasional (BSN), CAC, dan 11 negara lain yaitu Uni Eropa, Kanada, China, Korea Selatan, Vietnam, Amerika Serikat, Jepang, Malaysia, Singapura, Thailand, dan Australia. Hasil penelitian menunjukkan bahwa dari 164 notifikasi penolakan produk perikanan Indonesia di Uni Eropa, Kanada, dan Korea Selatan selama 10 tahun (2008-2017), penolakan produk perikanan tertinggi disebabkan oleh adanya cemaran kimia merkuri dan metilmerkuri pada ikan todak sebesar 27%, kadmium pada gurita sebesar 5% dan benzo[a]piren pada ikan asap sebesar 3%. Batas maksimum cemaran kimia untuk arsen, kadmium, dan timbal (pada ikan predator) di Indonesia yang terdapat pada Peraturan Kepala (Perka) BPOM Nomor 5 Tahun 2018 lebih rendah dibandingkan dengan yang terdapat di SNI 7387:2009 maupun yang ditetapkan oleh CAC serta negara lain. Indonesia telah menetapkan batas maksimum benzo[a]piren pada ikan asap, sementara itu CAC hanya menetapkan code of practice terhadap benzo[a]piren. Peraturan cemaran logam berat belum sepenuhnya dipedomani oleh para eksportir sehingga masih terdapat penolakan produk perikanan Indonesia. Hal ini menunjukkan masih perlu dilakukan pengawasan terkait kandungan logam berat yang terdapat pada produk perikanan di Indonesia. Code of practice terkait proses pengolahan pangan direkomendasikan untuk diterbitkan guna meminimalisir kandungan benzo[a]piren. Compliance Assessment of Chemical Contaminant Standard (Heavy Metal and PAH) for Fishery Products in Indonesia with those of Other Countries and CodexAbstractFood can be contaminated by chemical contamination through inappropriate food handling and processing. The purpose of this study aims to: 1) identify the chemical contamination caused majority of the rejection of Indonesia fishery products, 2) reviewing the chemical standards of contamination fishery products in Indonesia, Codex Alimentariurs Commision (CAC) and other countries, and 3) provide recommendations for the setting of chemical contamination standards in fishery products. Chemical contamination standards were collected from regulations issued by the Indonesia National Agency of Drug and Food Control (NADFC), National Standardization Agency of Indonesia, CAC, and 11 other countries: European Union/EU, Canada, China, South Korea, Vietnam, United States of America, Japan, Malaysia, Singapore, Thailand, and Australia. The results showed that in the 10 years period (2008-2017), there were 164 rejection notifications in EU, Canada, and South Korea and the highest rejection was caused by chemical contamination i.e. 27% caused by mercury and methylmercury in swordfish, 5% caused by cadmium in octopus and 3% caused by benzo[a]pyrene in smoked fish. The maximum limit of chemical contamination for arsenic, cadmium, and lead (predatory fish) in Indonesia as stated in the Regulation of the Head of NADFC Number 5 of 2018 lower than the maximum limit set in SNI 7387: 2009 and sets in CAC and other countries. Indonesia set the maximum limit for benzo[a]pyrene in smoked fish, whereas CAC published the code of practice to avoid a benzo[a]pyrene formation. Regulations of maximum limit for heavy metal contamination have not been fully guided by fisheries exporters, so that there was still rejection of Indonesian fishery products. The action needed is tightening the monitoring of heavy metal in fishery products in Indonesia. Code of practice to avoid benzo[a]pyrene formation is recommended to set up to minimize the benzo[a]pyrene formation on food processing.
18
GOWDA, Jeevan, Anwesha BEHERA, Annam Pavan KUMAR, and Ashok JAİSWAR. "First Record of Rhynchorhamphus naga Collette, 1976 (Beloniformes: Hemiramphidae) From Kerala, India, South Eastern Arabian Sea." Marine Science and Technology Bulletin 11, no. 4 (December 31, 2022): 533–39. http://dx.doi.org/10.33714/masteb.1182270.
Full textAbstract:
Species, under the genus Rhynchorhamphus (Family: Hemiramphidae), are widely distributed marine groups of fishes. Among four species described from India, only two species, i.e., Rhynchorhamphus georgii and R. maabarica, are reported along the Indian coast. However, during the present study, a specimen collected from the Western Indian Ocean, Chetty harbour, Kerala, the south-west coast of India, has been identified as Rhynchorhamphus naga (Collette, 1976), based on morphology and molecular characters. The species is characterized by D-14; A-14; Pec-9; Pev-6; GR-50 and a prolonged beak (171.82% HL). The species has been reported from Western Central Pacific and several other countries like Brunei Darussalam, Cambodia, Malaysia, Philippines, Singapore, Thailand and Vietnam considered to be endemic to that region. This finding reveals that the species has a wider distribution, as we recorded the species from Kerala, south-west coast of India along the Indian Ocean.
19
Wong, Zeng Hao, Chee Keong Chong, Bee Choo Tai, and Gilbert Lau. "A Review of Fatal Road Traffic Accidents in Singapore from 2000 to 2004." Annals of the Academy of Medicine, Singapore 38, no. 7 (July 15, 2009): 594–99. http://dx.doi.org/10.47102/annals-acadmedsg.v38n7p594.
Full textAbstract:
Introduction: This retrospective study aims to assess the epidemiology of road traffic accident (RTA) fatalities in Singapore, other causes of death besides trauma in a RTA, and identify the groups at risk. Materials and Methods: Data of 1038 RTA fatalities were reported between 2000 and 2004. Analyses using the Fisher’s exact test for discrete variables and multivariate Cox regression analysis were performed to identify groups at risk. The risk of fatality was measured using the prevalence rate ratio (PRR). Results: The median age of victims in the sample was 36 years (interquartile range 24 to 55). Eight hundred and thirty six cases (78%) were in the economically productive age range of 15 to 65 years. Over the 5-year period, there was a preponderance of males. Majority of fatalities involved multiple injuries. There were also 64 (6.2%) and 25 (2.4%) cases of RTA fatalities from infective and cardiovascular (CVS) causes, respectively. Multivariate analyses showed that those ≥ 60 years were 4 (95% CI of PRR, 3.04 to 5.43) times as likely to be pedestrian fatalities. Conversely, the risk of fatalities involving pedestrians and cyclists was reduced for males (PRR = 0.58; 95% CI, 0.46 to 0.73). However, males were at increased risk of fatalities involving motorcyclists, scooter and pillion riders (PRR = 1.96; 95% CI, 1.43 to 2.70), whereas such risk was reduced for those aged 30 to 59 (PRR = 0.70; 95% CI, 0.58 to 0.85) or ≥ 60 years (PRR = 0.30; 95% CI, 0.21 to 0.42), respectively. Conclusion: As such, it appears that the groups at-risk had varying demographic characteristics. Public education could be modified to target these different groups to reduce the number of fatalities. Key words: Fatality, Motorcyclists, Pedestrians, Risk, Road traffic accident(s)
20
Taira, D., EC Heery, LHL Loke, A. Teo, AG Bauman, and PA Todd. "Ecological engineering across organismal scales: trophic-mediated positive effects of microhabitat enhancement on fishes." Marine Ecology Progress Series 656 (December 10, 2020): 181–92. http://dx.doi.org/10.3354/meps13462.
Full textAbstract:
Retrofitting microhabitat features is a common ecological engineering technique for enhancing biodiversity and abundance of small, epilithic organisms on artificial shorelines by providing refuge spaces and/or ameliorating abiotic conditions. These features are typically too small to be utilised as refugia by larger, highly motile consumers such as fish, but they may affect these organisms through other mechanisms. This study sought to determine whether microhabitat enhancement units alter the fish abundance, richness and assemblage composition on tropical seawalls and explores possible underlying trophic mechanisms. We created 12 experimental plots consisting of 6 enhanced plots, each with 20 microhabitat enhancement tiles, and 6 control plots without tiles on intertidal seawalls at Pulau Hantu, an offshore island south of mainland Singapore. Benthic cover and fish assemblage were surveyed within each plot using photoquadrats and underwater video cameras, respectively, from April 2018 to February 2019. We found greater abundance and species richness and distinct assemblages of fish in the enhanced plots compared to the control plots. These differences were driven largely by an increase in both abundance and richness of fish species with epibenthic-feeding strategies and were significantly associated with higher biotic cover in the enhanced plots, especially epilithic algal matrix (EAM). Our results indicate that, in addition to facilitating epilithic organisms, microhabitat enhancement can provide food resources for epibenthic-feeding fishes, increase fish biodiversity, and alter fish assemblages in tropical urbanised shorelines.
21
Wardono, Budi, Rizky Muhartono, Tenny Apriliani, Hikmah, and Armen Zulham. "Traditional Fisheries Supply Chain Management in The Border Area: The Natuna Islands, Indonesia." E3S Web of Conferences 147 (2020): 02009. http://dx.doi.org/10.1051/e3sconf/202014702009.
Full textAbstract:
Fisheries have an important role in the economic and security aspects of the border region. Fishing in Natuna is carried out by local fishermen using small vessels with simple fishing gear. The distribution system with ships was hampered due to the Natuna sea area factors and the limited number and frequency. The research aimed to find out the supply chain management of fish in the Natuna Island border area to meet local, regional and export needs. The research used a qualitative approach and snowball information. The result showed that market formation was based on the type and quality of fish caught. Production of local fishermen was sold to the Natuna market, regional markets (Pontianak and Tanjung Pinang), and export market to Singapore, Mainland China, Hongkong, and Malaysia. Type of fish with premium quality (grouper, red snapper) was exported and sold to restaurants, with oligopolistic market characteristics. The premium quality fish market share was controlled by a large trader (Tauke) who has links to islands far Natuna (Pulau Laut, Pulau Tiga, Midai and Serasan). Non-premium quality fish marketing was carried out by fishing boat owners or collectors for local consumption and regional markets.
22
Uddin, Md Nagim, Mahabubur Rahman, Md Jakir Hossain, Israt Jahan Tumpa, and Zakir Hossain. "Study of stingray harvesting, marketing and utilization in Cox’s Bazar, Bangladesh." Journal of the Bangladesh Agricultural University 16, no. 3 (December 28, 2018): 539–44. http://dx.doi.org/10.3329/jbau.v16i3.39452.
Full textAbstract:
The present study was conducted to assess the harvesting procedures, nutritional value of stingray in the coastal district Cox’s Bazar, Bangladesh and its utilization as value-added product. Data were collected through direct observation, focus group discussion, questionnaire interview and cross check interview. It was found that stingray was mainly caught by artisanal fishery using gill net, set bag net and long line within 5-40 m depth ranges about 100-200 km at west direction, 10-60 km at south direction and 50-100 m depth ranges about 60-100 km at southwest direction from Fishery ghat, Cox’s Bazar. In the west direction, stingray harvesting grounds were Sonar char, Rupar char, Char Gongmoti and Dublar char in Patuakhali district, and Cox’s Bazar coast, Teknaf coast, St. Martin’s island coast and the south patches at south direction and middle ground at southwest direction. Generally stingrays was harvested throughout the year but were abundant during December and January. At fish landing center, the supply chain of stingray from fishermen to consumers passed through a number of intermediaries e.g., dealer, wholesaler, retailer and supplier. The market value of stingray varied where fishermen sold at 90-140 Tk/kg that passed through these channels and at last consumers got it at 140-250 Tk/kg. Six species of stingray were found in Fishery ghat, Cox’s Bazar namely Himantura gerrardi, Dasyatis bennetti, Himantura uarnak, Himantura undulata, Himantura bleekeri and Neotrygon kuhlii. Among them H. gerrardi and H. bleekeri were available and very popular in the market. The average moisture, protein, lipid, carbohydrate and ash content of H. bleekeri were determined as 78.08%, 14.80%, 4.31%, 0.95% and 1.87%, respectively and total energy content 103.78 Kcal. Three utilization processes were investigated in this study namely fish ball of stingray, stingray recipe with sour of tomato and stingray recipe with sour of tamarind. Fish ball was preferred as an excellent product and others were as very good products. Dried stingray products were only utilized by tribal peoples. Dried meat, skin and spine were exported abroad namely to China, Thailand, Myanmar and Singapore.
J. Bangladesh Agril. Univ. 16(3): 539–544, December 2018
23
Yong, Chean Yeah, Swee Keong Yeap, Abdul Rahman Omar, and Wen Siang Tan. "Advances in the study of nodavirus." PeerJ 5 (September 27, 2017): e3841. http://dx.doi.org/10.7717/peerj.3841.
Full textAbstract:
Nodaviruses are small bipartite RNA viruses which belong to the family ofNodaviridae. They are categorized into alpha-nodavirus, which infects insects, and beta-nodavirus, which infects fishes. Another distinct group of nodavirus infects shrimps and prawns, which has been proposed to be categorized as gamma-nodavirus. Our current review focuses mainly on recent studies performed on nodaviruses. Nodavirus can be transmitted vertically and horizontally. Recent outbreaks have been reported in China, Indonesia, Singapore and India, affecting the aquaculture industry. It also decreased mullet stock in the Caspian Sea. Histopathology and transmission electron microscopy (TEM) are used to examine the presence of nodaviruses in infected fishes and prawns. For classification, virus isolation followed by nucleotide sequencing are required. In contrast to partial sequence identification, profiling the whole transcriptome using next generation sequencing (NGS) offers a more comprehensive comparison and characterization of the virus. For rapid diagnosis of nodavirus, assays targeting the viral RNA based on reverse-transcription PCR (RT-PCR) such as microfluidic chips, reverse-transcription loop-mediated isothermal amplification (RT-LAMP) and RT-LAMP coupled with lateral flow dipstick (RT-LAMP-LFD) have been developed. Besides viral RNA detections, diagnosis based on immunological assays such as enzyme-linked immunosorbent assay (ELISA), immunodot and Western blotting have also been reported. In addition, immune responses of fish and prawn are also discussed. Overall, in fish, innate immunity, cellular type I interferon immunity and humoral immunity cooperatively prevent nodavirus infections, whereas prawns and shrimps adopt different immune mechanisms against nodavirus infections, through upregulation of superoxide anion, prophenoloxidase, superoxide dismutase (SOD), crustin, peroxinectin, anti-lipopolysaccharides and heat shock proteins (HSP). Potential vaccines for fishes and prawns based on inactivated viruses, recombinant proteins or DNA, either delivered through injection, oral feeding or immersion, are also discussed in detail. Lastly, a comprehensive review on nodavirus virus-like particles (VLPs) is presented. In recent years, studies on prawn nodavirus are mainly focused onMacrobrachium rosenbergiinodavirus (MrNV). RecombinantMrNV VLPs have been produced in prokaryotic and eukaryotic expression systems. Their roles as a nucleic acid delivery vehicle, a platform for vaccine development, a molecular tool for mechanism study and in solving the structures ofMrNV are intensively discussed.
24
Mok, Yee Hui, Amanda PT Loke, Tsee Foong Loh, and Jan Hau Lee. "Characteristics and Risk Factors for Mortality in Paediatric In-Hospital Cardiac Events in Singapore: Retrospective Single Centre Experience." Annals of the Academy of Medicine, Singapore 45, no. 12 (December 15, 2016): 534–41. http://dx.doi.org/10.47102/annals-acadmedsg.v45n12p534.
Full textAbstract:
Introduction: There is limited data on paediatric resuscitation outcomes in Asia. We aimed to describe outcomes of paediatric in-hospital cardiac arrests (IHCA) and peri-resuscitation factors associated with mortality in our institution. Materials and Methods: Using data from our hospital’s code registry from 2009 to 2014, we analysed all patients younger than 18 years of age with IHCA who required cardiopulmonary resuscitation (CPR). Exposure variables were obtained from clinical demographics, CPR and post-resuscitation data. Outcomes measured were: survival after initial CPR event and survival to hospital discharge. We analysed categorical and continuous variables with Fisher’s exact and Wilcoxon rank-sum tests respectively. Statistical significance was taken as P <0.05. Results: We identified 51 patients in the study period. Median age of patients was 1.9 (interquartile range [IQR]: 0.3, 5.5) years. Twenty-six (51%) patients had bradycardia as the first-recorded rhythm. The most common pre-existing medical condition was respiratory-related (n = 25, 48%). Thirty-eight (75%) achieved sustained return of spontaneous circulation, 24 (47%) survived to paediatric intensive care unit (PICU) discharge and 23 (45%) survived to hospital discharge. Risk factors for hospital mortality included: age, duration of CPR, adrenaline, calcium or bicarbonate administration during CPR, Paediatric Index of Mortality (PIM)-II scores, first recorded post-resuscitation pH and hyperglycaemia within 24 hours of resuscitation. Conclusion: We demonstrated an association between clinical demographics (age, PIM-II scores), CPR variables (duration of CPR and administration of adrenaline, calcium or bicarbonate) and post-resuscitation laboratory results (first recorded pH and hyperglycaemia within 24 hours) with PICU survival. The availability and quality of post-resuscitation care may have implications on survival after paediatric IHCA. Key words: Cardiopulmonary resuscitation, Child, Infant
25
Patoz, Aurélien, Thibault Lussiana, Cyrille Gindre, and Kim Hébert-Losier. "Recognition of Foot Strike Pattern in Asian Recreational Runners." Sports 7, no. 6 (June 17, 2019): 147. http://dx.doi.org/10.3390/sports7060147.
Full textAbstract:
Close to 90% of recreational runners rearfoot strike in a long-distance road race. This prevalence has been obtained from North American cohorts of runners. The prevalence of rearfoot strikers has not been extensively examined in an Asian population of recreational runners. Therefore, the aim of this study was to determine the prevalence of rearfoot, midfoot, and forefoot strikers during a long-distance road race in Asian recreational runners and compare this prevalence to reported values in the scientific literature. To do so, we classified the foot strike pattern of 950 recreational runners at the 10 km mark of the Singapore marathon (77% Asian field). We observed 71.1%, 16.6%, 1.7%, and 10.6% of rearfoot, midfoot, forefoot, and asymmetric strikers, respectively. Chi-squared tests revealed significant differences between our foot strike pattern distribution and those reported from North American cohorts (P < 0.001). Our foot strike pattern distribution was similar to one reported from elite half-marathon runners racing in Japan (Fisher exact test, P = 0.168). We conclude that the prevalence of rearfoot strikers is lower in Asian than North American recreational runners. Running research should consider and report ethnicity of participants given that ethnicity can potentially explain biomechanical differences in running patterns.
26
Cheong, Kah Wai, Yik Weng Yew, and Hong Liang Tey. "Idiopathic Generalized Exfoliative Dermatitis and Association with Antihypertensive Drugs and Statins: A Retrospective Case-Control Study." Dermatology 235, no. 2 (2019): 107–11. http://dx.doi.org/10.1159/000495836.
Full textAbstract:
Background/Aims: We aim to examine the hypothesis that antihypertensive drugs and statins may be responsible for the development of idiopathic generalized exfoliative dermatitis (GED) with a case-control study. Methods: All inpatients who were hospitalized under the dermatology service at the Tan Tock Seng Hospital, Singapore, between 1 May 2013 and 31 May 2015, were analysed. Idiopathic GED cases had consistent clinical and histological features but no apparent cause despite comprehensive evaluation. Controls were randomly selected from inpatients with other dermatological conditions in a 1: 1 ratio during the same period. Their relationship was analysed using univariate (χ2 or Fisher exact tests) and multivariate logistic regression analysis. Results: There were 78 cases and 83 controls. Of the 78 cases, 42 patients had a history of treatment with antihypertensive drugs or statins. Cases were not found to be more likely on angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, calcium channel blockers, thiazides or statins compared to controls (OR: 0.81; 95% CI: 0.43–1.51; p = 0.507). Conclusions: There was insufficient evidence to suggest a significant relationship between the chronic use of antihypertensive drugs or statins and idiopathic GED in this study, despite previous evidence reporting this might be so. Further case-control studies with larger sample sizes are needed to evaluate this association.
27
Diana, Farah, Hafinuddin Hafinuddin, and Muhajir Ansar. "PENGARUH JENIS UMPAN YANG BERBEDA TERHADAP HASIL TANGKAPAN KEPITING BAKAU (Scylla serrata) DENGAN MENGGUNAKAN ALAT TANGKAP BUBU." JURNAL PERIKANAN TROPIS 5, no. 2 (October 1, 2018): 119. http://dx.doi.org/10.35308/jpt.v5i2.1031.
Full textAbstract:
Mangrove crab (Scylla serrata) is one of the fishery commodities that have higheconomic value. In addition, mangrove crab is one of export commodities to several countries such as United States, Europe, Australia, Japan, Hongkong,Taiwan, Singapore and South Korea. In general, the fishing activities of mangrove crabs in the general waters of many fishermen use different baits,it's just not known which bait is best for catching mangrove crabs. The purpose ofthis study is to determine the effect of using different types of bait to the mangrove crab catch by using bubu and know the type of bait that is most effective against the catching of mangrove crab. This research method used Completely Randomized Design (RAL) with three treatments and three replications: P1 = shredded fish, P2 = Shark skin bark, and P3 = Chicken head bait. The parameters in this study are the number of catches, the feed response and the water quality parameters, the results of this study indicate the number of catches P1 = 55.55%, P2 = 22.22% and P3 = 33.33%. While feed response time in this research P1 = 1.61, P2 = 12.03, and P3 = 11.74. From the results of this study showed the use of different baits have a very significant effect on the number of mangrove crabs (scilla serata). While the feedback response also shows the results are very real (Fcal> Ftab).
28
BikramJit, Roy, Nripendra Kumar Singha, Hasan Ali, Gaziur Rhaman, and Fukrul Alam. "SHARK FISHERIES EXPLOITATION, TRADE, CONSERVATION AND MANAGEMENTIN THE BAY OF BENGAL OF BANGLADESH REGION." International Journal of Research -GRANTHAALAYAH 2, no. 2 (November 30, 2014): 69–83. http://dx.doi.org/10.29121/granthaalayah.v2.i2.2014.3068.
Full textAbstract:
The study was conducted during July, 2003 to June, 2013 about landing volumes of shark fishery (sharks and rays) in artisanal and industrial fishing sector only in group- wise not in species wise. In these periods, in artisanal fisheries gill nets (shark nets), set bag nets, long lines and trammel nets exploiting data were analyzed. But from 2012-13 periods in industrial fisheries harvesting data of sharks and rays by trawl fishing were started to record keeping in group wise. During 2012-13 total sharks and rays landing volume contributes only 0.85% (5017 MT) of total the marine fish production of Bangladesh.8
During 2010-11 to 2012-13 no sharks and rays product items had been traded from Bangladesh due to international market ban But from 2003-04 to 2009-10 period sharks and rays product with fish maws export to the Myanmar, India, Singapore, Thailand, Hong Kong, China, USA and other countries. Dried and iced sliced meat of shark and rays, its sun-dried hide, bones, fins, tails, teeth and shark liver oil all are sold for local consumers, but only sets of fins (2 pectoral, 2 pelvic, 1 dorsal, 2 anal and 1 caudal fin) and skins were exporting to the foreign markets, which has been stopped now. In the year 2009-10 total 955 MT of sharks and rays product (with fish maws) were exporting and earning (app.) USD 1.60 million. For the conservation and management of shark fishery need National Plan of Action, which exploiting in the MSY and help to banning of critically endangered sharks and rays species. Appropriate law in the Fish Act (at present Fish Act has no forms of restriction for harvesting sharks, while Forestry Act restricts it in Sundarbans area) for sustainable harvesting and conservation of the elasmobranchs. Such law should include how many boats (motorized- and non-motorized) and industrial trawlers could be allowed to harvest sharks from which area, in which season and the allowable limit of harvests; in every case proper ways of fishing methods should strictly be followed. Coastal areas around Saint Martin’s Island and Sundarbans proposed by the Bay of Bengal should be declared as Marine Protected Area as most sharks use these areas as their nursing grounds.
29
Pane, Andina Ramadhani Putri, Reza Alnanda, and Ali Suman. "STATUS PEMANFAATAN PERIKANAN KEPITING MERAH (Scylla olivacea) DI PERAIRAN MIMIKA DAN SEKITARNYA, PAPUA." Marine Fisheries : Journal of Marine Fisheries Technology and Management 11, no. 1 (August 10, 2020): 1–12. http://dx.doi.org/10.29244/jmf.v11i1.28168.
Full textAbstract:
Red mud crab (Scylla olivacea) is an economic commodity that is traded into foreign countries such as China, Malaysia, and Singapore so that fishing activities are carried out intensively. Therefore, we need scientific information about the status of red mud crab fishery stock. Information about the natural mortality, fishing mortality, and the exploitation level of crabs can be used as the basis for crab fisheries management. The study was conducted for 2 (two) years, February to October 2017, and March to December 2018 using the survey method. The results showed that 36% of the crabs were caught below the 120 mm size as regulated in Regulation of the Minister of Marine Affairs and Fisheries No. 12 Year 2020. The carapace width of the first capture (CWc) is smaller than the size of the carapace width of the first gonad maturity (CWm). This shows that the crab has been captured before the first gonad maturity (CWc < CWm). The growth rate (K) is 0.65 per year with fishing mortality (F) higher than natural mortality (M). Exploitation level (E) 0.70 which indicates that the status fisheries of red mud crab in Mimika have been overexploited. Efforts need to be done by the Regional Government in collaboration with local community leaders in providing counseling and information about the size of red mud crabs that can be caught and reduce efforts to use crabs by as much as 40% of what is currently done.
Keywords: status explotation, red mud crabs, Mimika, FMA 718
30
Sugiartiningsih, Sugiartiningsih. "PENGARUH INFLASI INDONESIA TERHADAP PENERIMAAN PENANAMAN MODAL ASING LANGSUNG KOREA SELATAN DI INDONESIA PERIODE 2000-2014." Jurnal Manajemen Maranatha 17, no. 1 (November 9, 2017): 33. http://dx.doi.org/10.28932/jmm.v17i1.416.
Full textAbstract:
One of the keys to success in improving the economic prosperity of a country is evident from its response to bilateral or multilateral relations, particularly in the making of investments. Indonesia as a country that has started the construction of the New Order can not be separated from the role of foreign capital. In reality in the 1990s looks acceptance by the Indonesian foreign capital is relatively low compared to the developing countries in Asia. China is the largest recipient of foreign capital, followed by Singapore and Malaysia. In more remote Indonesian government continues its efforts to increase Foreign direct investment, especially from South Korea. As we all know South Korea is an important trading partner for Indonesia. Indonesia bilateral relations with South Korea have occurred since the New Order and has impacted the relatively low added value for Indonesia, especially in the 1990s. In the development of bilateral relations between the two countries increased, especially after entering the Reformation Era. This condition is supported by inflation in Indonesia is considered quite stable. This study aims to determine the effect of inflation on the acceptance Indonesia Foreign direct investment from South Korea to Indonesia during the period 2000-2014. The research methodology used is quantitative approach using simple regression model. Based on the results of the calculations, and a significant negative correlation between inflation in Indonesia and the acceptance of Direct Foreign Investment from South Korea in Indonesia. This is consistent with Fisher's theory that the decline in inflation Indonesia will be followed by a decline in interest rates Indonesia which ultimately impact the increased investment in Indonesia. Besides these reasons, the negative relationship, emphasizing that the investment climate in Indonesia has improved so trust Foreign investors, especially from South Korea in Indonesia is quite large. Keywords: Foreign direct investment, inflation in Indonesia
31
Xu, C., K. P. Leong, M. Y. Yong, and E. T. Koh. "AB0270 THE IMPACT OF DIABETES MELLITUS ON OUTCOMES OF RHEUMATOID ARTHRITIS AT 5-YEAR FOLLOW-UP: RESULTS FROM A MULTI-ETHNIC ASIAN COHORT IN SINGAPORE." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1433.2–1434. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5203.
Full textAbstract:
Background:Both diabetes mellitus (DM) and rheumatoid arthritis (RA) are prevalent diseases and represent the leading causes of disability and mortality worldwide. Systemic chronic inflammation is recognized as the underlying etiology of a variety of diseases, including DM and RA [1]. Additionally, cardiovascular and musculoskeletal complications from DM may influence the outcomes of RA patients.Objectives:To investigate the impact of DM on outcomes of RA patients.Methods:This is a cross-sectional study including 583 RA patients with 5 years’ history after diagnosis in Tan Tock Seng Hospital RA registry, Singapore from 2001 to 2013. Information related to demographics, serologies, clinical features, comorbidities, and outcomes was collected. Independent t-test or Mann-Whitney U test was used to compare continuous quantitative data, while Pearson Chi-square or Fisher Exact test for categorical data. With adjustment for age, gender, ethnicity, smoking and comorbidities, multivariate regressions were performed to analyze the impact of DM on outcomes of RA patients.Results:DM is more prevalent in Malay and Indian patients than Chinese patients with RA (26%, 24% and 11% respectively,p= 0.005). There is no difference of disease activity between DM and non DM patients. There is a tendency that non diabetic RA patients use more methotrexate (p= 0.052) and leflunomide (p= 0.058). Diabetic RA patients are in higher risk of poor American College of Rheumatology (ACR) functional status (p= 0.009), knee arthroplasty (p< 0.001) and admissions (p= 0.006). Adjusted for age, gender, ethnicity, smoking and comorbidities, multivariate regression analyses showed a trend of poor function status for diabetic RA patients, i.e. ACR functional status (adjusted odds ratio [aOR]: 1.802, 95% confidence interval [CI]: 0.968 – 3.353,p= 0.063) and median Health Assessment Questionnaire (HAQ) (β coefficient value: 0.129, 95% CI: -0.010 – 0.267,p= 0.068), and higher risk for knee arthroplasty for diabetic RA patients (aOR: 3.480, 95% CI: 1.016 – 11.920,p= 0.047).Conclusion:This is the first report on the impact of DM on RA outcomes in a long term follow-up RA registry in a multiethnic Asian society.References:[1]Furman, D., Campisi, J., Verdin, E.et al.Chronic inflammation in the etiology of disease across the life span.Nat Med25,1822–1832 (2019).Acknowledgments:TTSH Rheumatoid Arthritis Study GroupDisclosure of Interests:None declared
32
Braum, E. "Joseph S. Nelson: Fishes of the World. 2nd edition. — 523 pp. New York/Chichester/Brisbane/Toronto/Singapore: John Wiley & Sons 1984. ISBN 0-471-86475-7. 46.5 p.s." Internationale Revue der gesamten Hydrobiologie und Hydrographie 73, no. 1 (1988): 128. http://dx.doi.org/10.1002/iroh.19880730122.
Full text
33
Athanassopoulou, F., R. Cawthorn, and K. Lytra. "Amoeba-like Infections in Cultured Marine Fishes: Systemic Infection in Pompano Trachinotus falcatus L. from Singapore and Gill Disease Associated with Paramoeba sp. in Sea Bream Sparus aurata L. from Greece." Journal of Veterinary Medicine Series B 49, no. 8 (October 2002): 411–12. http://dx.doi.org/10.1046/j.1439-0450.2002.00583.x.
Full text
34
Chan, Sze Ling, Joshua Jun Wen Low, Kee Seng Chia, and Hwee-Lin Wee. "ATTITUDES ON WARFARIN PHARMACOGENETIC TESTING IN CHINESE PATIENTS AND PUBLIC." International Journal of Technology Assessment in Health Care 30, no. 1 (January 2014): 113–20. http://dx.doi.org/10.1017/s026646231300069x.
Full textAbstract:
Introduction: Genetic factors affecting warfarin maintenance dose have been well established, but patient acceptance is a necessary consideration for the successful clinical implementation of warfarin pharmacogenetic testing (WPGT). In this study, we aimed to determine the attitudes toward WPGT among Singaporean Chinese.Methods: A total of 194 warfarin patients and 187 members of the public completed a structured survey on paper and the Internet, respectively. Attitudes were expressed as willingness to undergo WPGT (single item with 5-point response) and expectations and concerns about WPGT (two multi-item scales). Relationships between attitudes and socio-demographic and clinical variables were explored using Fisher's exact test, Student's t-test, one-way analysis of variance or Pearson's correlation.Results: Majority of respondents were willing to or neutral about undergoing WPGT. Both patients and public had relatively high expectations (mean [SD]: 3.77 [0.63], and 3.97 [0.55], respectively) and moderately high concerns (mean [SD]: 3.30 [0.69] and 3.33 [0.68], respectively) about WPGT. Willingness to undergo WPGT was associated with gender, educational status, length of warfarin treatment, and number of chronic diseases among warfarin patients, and with history of adverse drug reactions and number of chronic diseases among the public. Higher expectation of WPGT was associated with higher willingness (p < .001 in both populations), while higher concern was associated with lower willingness to undergo WPGT among the public (p = .004) but not among patients (p = .072).Conclusion: Patient acceptance is not a major barrier to clinical implementation of WPGT but patient education is necessary and the ethical, social, and legal issues should be addressed.
35
Tan, Hui Shan, Alvin Seng Cheong Wong, Kian Tai Chong, Siew Wei Wong, Marniza Bte Saad, Chi-Fai Ng, Shigeo Horie, et al. "AR-V7 in Asian patients with metastatic CRPC: A multinational, multicentre study." Journal of Clinical Oncology 36, no. 6_suppl (February 20, 2018): TPS401. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.tps401.
Full textAbstract:
TPS401 Background: The detection of androgen-receptor splice variant 7 (AR-V7) mRNA transcript in circulating tumor cells (CTCs) of progressive metastatic castration-resistant prostate cancer (mCRPC) patients is associated with resistance to abiraterone and enzalutamide. This finding was validated by other studies that found no association between the presence of AR-V7 transcripts and response to both docetaxel and cabazitaxel. The results suggest that AR-V7 could represent a biomarker to guide treatment selection in mCRPC. However, data in Asian population is limited. This multinational study aims to prospectively investigate the incidence and prevalence of ARV7 in Asian mCRPC patients. This is also the first study to evaluate 3 different detection platforms and help provide guidance on which will be the best platform to carry forward in terms of clinical utility. Methods: 101 Asian subjects with histologically confirmed mCRPC whom are going to be treated with AR-directed therapies (abiraterone, enzalutamide) or taxane chemotherapy (docetaxel) will be enrolled from Singapore, Malaysia, Thailand, Hong Kong and Japan. Subjects will be excluded if they plan to receive additional concurrent anticancer therapies. Peripheral-blood samples will be obtained at baseline and at the time of progression. We will use 3 methods to analyse the samples: (i) CTC enrichment platform followed by automated immunofluorescent staining for DNA, cytokeratins, CD45 (lymphocyte common antigen), and AR-V7; (ii) CTC enrichment platform followed by reverse-transcription polymerase chain reaction analysis; and (iii) the AdnaTest platform for molecular characterization of CTCs. Subjects will be followed up to 2 years. The clinical outcomes of AR-V7-positive and AR-V7-negative patients will be compared. PSA response rates will be compared using the Fisher exact test. Time-to-event outcomes (PFS, OS) will be evaluated using Kaplan-Meier analysis, and survival time differences will be compared using log-rank test. Cox regression analyses will be used to assess the effect of AR-V7 status in predicting clinical outcomes. The study is in progress; 32 of 101 planned patients have been enrolled at the end of September 2017.
36
KITLV, Redactie. "Book reviews." Bijdragen tot de taal-, land- en volkenkunde / Journal of the Humanities and Social Sciences of Southeast Asia 161, no. 4 (2009): 517–75. http://dx.doi.org/10.1163/22134379-90003706.
Full textAbstract:
Sitor Situmorang, Toba na Sae; Sejarah lembaga sosial politik abad XIII-XX (Johann Angerler) Raul Pertierra, Science, technology, and everyday culture in the Philippines (Greg Bankoff) Françoise Gérard and François Ruf (eds), Agriculture in crisis; People, commodities and natural resources in Indonesia, 1996-2000 (Peter Boomgaard) Kennet Sillander, Acting authoritatively; How authority is expressed through social action among the Bentian of Indonesian Borneo (Aurora Donzelli) Kathleen M. Nadeau, Liberation theology in the Philippines; Faith in a revolution (Gareth Fisher) Roy Ellen, On the edge of the Banda Zone; Past and present in the social organization of a Moluccan trading network (Gregory Forth) Roy Ellen, On the edge of the Banda Zone; Past and present in the social organization of a Moluccan trading network (J.M. Gullick) I.H.N. Evans, Bornean diaries, 1938-1942 (Fiona Harris) S. Margana, Kraton Surakarta dan Yogyakarta 1769-1874 (Mason C. Hoadley) Henry Frei, Guns of February; Ordinary Japanese soldiers’ views of the Malayan campaign and the fall of Singapore 1941-42 (Russell Jones) Gerrit Knaap and Heather Sutherland, Monsoon traders; Ships, skippers and commodities in eighteenth-century Makassar (J. Thomas Lindblad) David W. Fraser and Barbara G. Fraser, Mantles of merit; Chin textiles from Myanmar, India and Bangladesh (Sandra A. Niessen) Kees Snoek, E. du Perron; Het leven van een smalle mens (Frank Okker) Arthur J. Dommen, The Indochinese experience of the French and the Americans; Nationalism and communism in Cambodia, Laos and Vietnam (Vatthana Pholsena) J.H.M.C. Boelaars and A.C. Blom, Mono Koame; ‘Wij denken ook’ (Anton Ploeg) James J. Fox and Dionisio Babo Soares (eds), Out of the ashes; Destruction and reconstruction of East Timor (Johanna van Reenen) Anke Niehof and Firman Lubis (eds), Two is enough; Family planning in Indonesia under the New Order 1968-1998 (Elisabeth Schröder-Butterfill) Andrew MacIntyre, The power of institutions; Political architecture and governance (Henk Schulte Nordholt) Carol Ireson-Doolittle and Geraldine Moreno-Black, The Lao; Gender, power, and livelihood (Guido Sprenger) David L. Gosling (with a foreword by Ninian Smart), Religion and ecology in India and Southeast Asia (Bryan S. Turner) William C. Clarke, Remembering Papua New Guinea; An eccentric ethnography (Donald Tuzin) Review essay Gerben Nooteboom: Competition, collateral damage, or ‘just accidents’? Three explanations of ethnic violence in Indonesia: - Jacques Bertrand, Nationalism and ethnic conflict in Indonesia - Cristina Eghenter, Bernard Sellato, and G. Simon Devung (eds), Social science research and conservation management in the interior of Borneo; Unravelling past and present interactions of people and forests - Nancy Lee Peluso and Michael Watts (eds), Violent environments - Günther Schlee (ed.), Imagined differences; Hatred and the construction of identity
37
Chan, Mark Y., Motakis Efthymios, Sock Hwee Tan, John W. Pickering, Richard Troughton, Christopher Pemberton, Hee-Hwa Ho, et al. "Prioritizing Candidates of Post–Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics." Circulation 142, no. 15 (October 13, 2020): 1408–21. http://dx.doi.org/10.1161/circulationaha.119.045158.
Full textAbstract:
Background: Heart failure (HF) is the most common long-term complication of acute myocardial infarction (MI). Understanding plasma proteins associated with post-MI HF and their gene expression may identify new candidates for biomarker and drug target discovery. Methods: We used aptamer-based affinity-capture plasma proteomics to measure 1305 plasma proteins at 1 month post-MI in a New Zealand cohort (CDCS [Coronary Disease Cohort Study]) including 181 patients post-MI who were subsequently hospitalized for HF in comparison with 250 patients post-MI who remained event free over a median follow-up of 4.9 years. We then correlated plasma proteins with left ventricular ejection fraction measured at 4 months post-MI and identified proteins potentially coregulated in post-MI HF using weighted gene co-expression network analysis. A Singapore cohort (IMMACULATE [Improving Outcomes in Myocardial Infarction through Reversal of Cardiac Remodelling]) of 223 patients post-MI, of which 33 patients were hospitalized for HF (median follow-up, 2.0 years), was used for further candidate enrichment of plasma proteins by using Fisher meta-analysis, resampling-based statistical testing, and machine learning. We then cross-referenced differentially expressed proteins with their differentially expressed genes from single-cell transcriptomes of nonmyocyte cardiac cells isolated from a murine MI model, and single-cell and single-nucleus transcriptomes of cardiac myocytes from murine HF models and human patients with HF. Results: In the CDCS cohort, 212 differentially expressed plasma proteins were significantly associated with subsequent HF events. Of these, 96 correlated with left ventricular ejection fraction measured at 4 months post-MI. Weighted gene co-expression network analysis prioritized 63 of the 212 proteins that demonstrated significantly higher correlations among patients who developed post-MI HF in comparison with event-free controls (data set 1). Cross-cohort meta-analysis of the IMMACULATE cohort identified 36 plasma proteins associated with post-MI HF (data set 2), whereas single-cell transcriptomes identified 15 gene-protein candidates (data set 3). The majority of prioritized proteins were of matricellular origin. The 6 most highly enriched proteins that were common to all 3 data sets included well-established biomarkers of post-MI HF: N-terminal B-type natriuretic peptide and troponin T, and newly emergent biomarkers, angiopoietin-2, thrombospondin-2, latent transforming growth factor-β binding protein-4, and follistatin-related protein-3, as well. Conclusions: Large-scale human plasma proteomics, cross-referenced to unbiased cardiac transcriptomics at single-cell resolution, prioritized protein candidates associated with post-MI HF for further mechanistic and clinical validation.
38
UIBLEIN, FRANZ, DANIEL C. GLEDHILL, DIMITRI A. PAVLOV, TUAN ANH HOANG, and SHAKER SHAHEEN. "Three new goatfishes of the genus Upeneus (Mullidae) from the Indo-Pacific, with a redescription of colour patterns in U. margarethae." Zootaxa 4683, no. 2 (October 8, 2019): 151–96. http://dx.doi.org/10.11646/zootaxa.4683.2.1.
Full textAbstract:
For the goatfish genus Upeneus Cuvier 1829 (Mullidae), a new taxonomic species group called the “margarethae group” is established which can be distinguished from the six species of the most similar “tragula group” by a combination of the following characteristics: absence of dark pigmentation in the area of the first dorsal-fin tip, 21–25 total gill rakers and 28–30 lateral-line scales. Initially, three recently-described species have been included in the margarethae group: Upeneus margarethae Uiblein & Heemstra, 2010, known from the Indian Ocean including the Red Sea and from the Arafura Sea (W Pacific), U. mouthami Randall & Kulbicki, 2006, from New Caledonia and Vanuatu (W Pacific), and U. randalli Uiblein & Heemstra, 2011, from the Arabian/Persian Gulf and the inner Gulf of Oman (NW Indian Ocean). The present taxonomic review of the margarethae group analyses a large data set of 41 morphometric, 10 meristic and many colour characters obtained from 279 preserved goatfish specimens and 166 fresh-colour photos (plus a fresh-colour drawing). For the nominal species of the group, U. margarethae, a redescription of the colour patterns is provided and new records for Myanmar, Andaman Sea (NE Indian Ocean) and the Gulf of Carpentaria, N Australia (W Pacific), are reported. Three new species are described: U. caudofasciatus n. sp. from the area of the Great Barrier Reef to Torres Strait off NE Australia (Coral Sea, W Pacific), U. gubal n. sp. from the S Gulf of Suez (Northern Red Sea), and U. heterospinus n. sp. from S Indonesia to Singapore, the Gulf of Thailand, Vietnam, Philippines, China, Taiwan and Japan (W Pacific). A comprehensive alpha-taxonomic approach is adopted, considering population differences as well as intraspecific size-related variation in morphology and colour patterns by splitting the data set into two size classes, adults (≥ 65 mm SL) and smaller subadults. Inter- and intraspecific comparisons include statistical analyses for species and population with sufficiently large samples sizes (n ≥ 20). Colour-pattern characterization and analysis are based on photos of recently collected and deceased fish (partly associated with voucher specimens), photos obtained from active or resting fishes in situ or in a tank, and inspection of pigmentation patterns retained in preserved specimens. Species differences are elaborated under consideration of distribution patterns and the characteristics found in the closest-most population of widely distributed species such as U. margarethae, resulting in clear and consistent distinction among the six species in single or in a combination of several characteristics. Comparisons among size classes revealed species-specific patterns in morphometric, meristic and colour changes with increasing size. One species, U. heterospinus n. sp., has seven or eight spines in the dorsal fin which occur in balanced ratio across populations. This is a unique characteristic for Upeneus species which usually have either seven or eight dorsal-fin spines, respectively. The best distinction of Upeneus heterospinus n. sp. from all other congeners is reached by combined examination of dorsal-fin spines with several other characters such as barbel colour, presence of a mid-lateral body stripe, pigmentation patterns (partly retained also in preserved fish), gill-raker and pectoral-fin ray numbers, and body-shape variables. The high degree of overall morphological differentation among the three most common species U. caudofasciatus n. sp., U. heterospinus n. sp. and U. margarethae, as revealed by the statistical comparisons, strongly contrasts with a still signficant, but much lower degree of differentiation among populations. The diagnostic characteristics of the margarethae group are updated and the importance to use the results of this taxonomic review in ongoing fisheries-related and ecological research is emphasized. Requirements for future taxonomic research featuring the stunning diversity of the goatfish genus Upeneus are also discussed.
39
Chen, Yunxin, Chandramouli Nagarajan, Nicholas Francis Grigoropoulos, Shin-Yeu Ong, Kit Yan Loh, Allan Zhi Kai Goh, Yeow Tee Goh, and Yuh Shan Lee. "Impact of Incomplete Cycles and Dose Attenuation of Rituximab-Bendamustine on Survival Outcomes in Low-Grade Non-Hodgkin Lymphomas." Blood 132, Supplement 1 (November 29, 2018): 4165. http://dx.doi.org/10.1182/blood-2018-99-112732.
Full textAbstract:
Abstract Introduction Rituximab and Bendamustine (BR) has been shown to be effective in the treatment of indolent non-Hodgkin's lymphomas (NHLs) with an acceptable safety profile and comparable to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP). However, patients may develop significant cytopenias after Bendamustine exposure leading managing physicians to truncate the suggested treatment course or attenuate treatment dosages. We hypothesize that this reduced treatment intensity may negatively affect treatment outcomes. Methods We retrospectively analysed patients who were diagnosed with indolent non-Hodgkin lymphomas (NHL) at the Singapore General Hospital from year 2000 and received BR or R-CHOP frontline. Data was locked at 31 October 2017. Histologic diagnosis was made according to published international guidelines. The safety and efficacy of BR and RCHOP as first line treatment of indolent lymphomas was analyzed. We also evaluated if truncation of immunochemotherapy cycles or dosage attenuation impacts on progression-free survival (PFS). We define patients on BR as i) BR full - having received 6 cycles of BR at 90mg/m2/day for 2 days per cycle ii) BR attenuated - received at least 6 cycles of BR at 70mg/m2/day for 2 days per cycle iii) BR truncated - received less than 6 cycles of BR. The chi-squared and Fisher's exact two-sided tests were used for comparisons between categorical variables and the t-test was used for continuous variables. Survival probabilities were calculated using the Kaplan-Meier estimator, with log-rank analysis used to compare between different groups. All analyses were performed using Stata (Statacorp, College Station, TX, USA). Results Eighty-seven patients were evaluable of whom 47 received BR and 40 received R-CHOP upfront. Amongst patients who received BR and R-CHOP respectively, histological diagnoses were: follicular lymphoma (19.2% vs 72.5%), marginal zone lymphoma (25.5% vs 7.5%), chronic lymphocytic leukaemia / small B-cell lymphocytic lymphoma (29.8% vs 5.0%), lymphoplasmacytic lymphoma (21.3% vs 7.5%), mantle cell lymphoma (2.1% vs 5.0%) and other B-cell lymphoma not classifiable (2.1% vs 2.5%). Baseline characteristics are presented in Table 1 and treatment related toxicities are presented in Table 2. There was no significant difference in treatment emergent grades 3/4 haematological adverse events between BR and R-CHOP. More patients developed infusional reactions (17.0% vs 2.5%, p =0.04) when treated with BR compared to R-CHOP. Conversely, more patients treated with R-CHOP developed peripheral neuropathy (15.0% vs 0%, p=0.008). More patients who were treated with BR as compared to R-CHOP had treatment truncated (i.e. received less than 6 cycles) or dosages attenuated (46.8% vs 5.0%, p<0.005). The median number of cycles completed for patients who had BR treatment course truncated was 4 (interquartile range 2-4). For patients treated with BR, the reasons for treatment truncation were drug-related toxicity (17.0%), patient's decision (10.6%) and physician's decision (2.1%). 2 patients had early termination with R-CHOP treatment, 1 (2.5%) due to disease progression and another patient (2.5%) due to drug-related toxicity. With a median follow-up of 51.0 months, median PFS for patients treated with BR was 69.5 months versus 76.9 months for patients treated with R-CHOP (p=0.26). BR truncated patients had inferior PFS compared to BR full and BR attenuated patients (Median PFS = 36.5mths vs NR, p=0.01). There was no statistically significant difference in PFS between BR full and BR attenuated patients (Median PFS = 69.5 mths vs NR, p=0.25). Conclusion Treatment efficacies and haematological toxicities were comparable in our patients with indolent NHLs treated with BR or R-CHOP. Despite this, more patients treated with BR had treatment truncated prematurely. The majority of such terminations were for drug-related toxicities. We found inferior PFS in patients who received less than 6 cycles of BR. Patients who completed 6 cycles of BR but had attenuated dosages did not have inferior PFS compared to patients who received 6 cycles of BR at full dose. Our findings suggest that treatment truncation with reduced treatment intensity negatively affects survival outcomes. Patients with cytopenias should be supported or have drug dosages attenuated with the aim to complete the entire treatment course for best outcomes. Disclosures Chen: Takeda: Honoraria, Other: Travel grant; Janssen: Honoraria; Celgene: Honoraria; Amgen: Membership on an entity's Board of Directors or advisory committees, Other: Travel grant, Research Funding. Goh:Novartis AG: Honoraria, Other: Non-financial support, Research Funding; Takeda: Other: Non-financial support, Research Funding.
40
Andayani, Friska Tri, and Endang Ekowarni. "Peran Relasi Orang Tua-Anak dan Tekanan Teman Sebaya terhadap Kecenderungan Perilaku Pengambilan Risiko." Gadjah Mada Journal of Psychology (GamaJoP) 2, no. 2 (February 6, 2018): 138. http://dx.doi.org/10.22146/gamajop.33097.
Full textAbstract:
Alsa, A. (2014). Pendekatan kualitatif dan kuantitatif serta kombinasinya dalam penelitian psikologi. Cetakan V. Yogyakarta: Pustaka Pelajar.Badan Koordinasi Keluraga Berencana Nasional (BKKBN). (2011). Kajian profil penduduk remaja (10-24 tahun): Ada apa dengan remaja. Policy Brief Puslitbang Kependudukan. Retrieved fromhttp://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin%20reproduksi%20remaja-ed.pdfBadan Pusat Statistik (BPS). (2012). Survei demografi dan kesehatan Indonesia 2012. Kesehatan Reproduksi remaja. Jakarta: Kementerian Kesehatan Jakarta. Retrieved from http://www.bkkbn.go.id/litbang/pusdu/Hasil%20Penelitian/SDKI%202012/Laporan%20Pendahuluan%20REMAJA%20SDKI%202012.pdfBadan Pusat Statistik Provinsi D.I. Yogyakarta. (2015). Statistik politik dan keamanan Provinsi Daerah Istimewa Yogyakarta. Yogyakarta: Badan Pusat Statistik.Baumrind, D., Larzele, R. E., & Owens, E. B. (2010). Effect of preschool parents’ power assertive patterns ang practise on adolescent development. Parenting Science and Practice, 10(3), 157-201.Bonino, Cattelino, & Clairano,. (2005). Adolescents and risk, behavior, functions, and protective factors. Italia: Springer.Burt, S.A., McGue, M., Lacono, W.G., & Krueger, R.F. (2006). Differential parent–childrelationships and adolescent externalizing symptoms: Cross-lagged analyses within a monozygotic twin differences design. Devevelopmental Psychology, 42, 1289–1298.Chein, J., Albert, D., O’Brien, L., Uckert, K., & Steiberg, L. (2011). Peer increase adolescent risk taking by enhancing activity in the brain’s reward circuitry. Journal Development Science, 14(2), F1-F10.Choo, H., & Shek, D. (2013). Quality of parent-child relationship, family conflic, peer pressure, and drinking behaviours of adolescents in an Asian context: the case of Singapore. Social Indication Rescue, 110, 1141-1157.Clasen, D. R., & Brown, B. B. (1987). Understanding peer pressure in the middle school. Journal of Adolescence, 19(1), 21-23.Crawford, L. A., & Novak, K. B. (2002). Parental and peer influences on adolescent drinking: The relative impact of attachment and opportunity. Journal of Child & Adolescent Substance Abuse, 12(1), 1-26.Crockett, L. J., Raffaelli, M., & Shen, Y. L. (2006). Linking self-regulation and risk proneness to risky sexual behavior: Pathways through peer pressure and early substance use. Journal of Research on Adolescence, 16(4), 503-525.Derek, K., & Smiler, A. P. (2013). Norms and peer pressure in adolescent boys and girls alcohol use, Substance Use Misuse, 48(5), 371-378.DiClemente, R. J., Santelli, J. S., & Crosby, R. A. (2009). Adolescent health. Understanding and preventing risk behaviour. San Franscisco: Jossey-Bass: A Wiley Imprint.Dixson, M., Bermes, E., & Fair, S. (2014). An Instrument to investigate expectations about and experiences of the parent-child relationship: The parent-child relationship schema scale. Social Science, 3, 84-114.Eaton, D. K., Kann, L. & Kinchen, S. (2006). Youth risk behavior surveillance. Division of Adolescent and School Health, National Center for Chronic Disease Prevention and Health Promotion,55(5),1-108.Faska. (2015, April 5). Pernikahan dini di Jogja meningkat tajam. Pojoksatu. Retrieved fromhttp://pojoksatu.id/news/berita-nasional/2015/04/05/pernikahan-dini-di-jogja-meningkat-tajam/Fisher, L., & Feldman, S. S. (1998). Familial antecedents of young adulth health risk behavior: A longitudinal study. Journal of Family, 12(1), 68-80.Gardner, M. & Steinberg, L. (2005). Peer influence on risk taking, risk preference, and risky decision making in adolescence and adulthood: An experimental study. Developmental Psychology, 41(4), 625–635.Garnefski, N., & Diekstra, R. F. W. (1996). Perceived social support from family, school, and peers: Relationship with emotional and behavioral problem among adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 35(12), 1657-1664.Gheorghiu, A., Delhomme, P., & Felonneau, M. L. (2015). Peer pressure and risk taking in young drivers’ speeding behavior. Transportation Research Part F, 35, 101–111.Ghozali, I. (2011). Aplikasi analisis multivariat dengan program IBM SPSS 19, Edisi kelima. Semarang: Universitas Diponegoro.Gullone, E. & Moore, S. (2000). Developing adolescents: A reference for professionals. Washington DC: American Psychological Association.Informasi Kementerian Pemuda dan Olahraga. (2009). Kementerian pemuda dan olahraga. Biro Perencanaan: Sekretariat Kementerian Pemuda dan Olahraga.Jahun, K. (2011). Patterns of parent-child relationship quality, parent depression and adolescent development outcomes (Disertasi tidak terpublikasi). University of Washington, School of Nursing. Jessor, R., & Jessor, T. (2009). Description versus explanation in cross-national research on adolescent. Journal of Adolescent Health, 43(6), 527-528.Jessor, R., Turbin, M.S., Costa, F.M., Dong, Q., Zhang, H., & Wang, C. (2003). Adolescent problem behavior in China and the United States: A cross-national study of psychosocial protective factors. Journal of Adolescence Research,13, 329–360.Johnson, & Matthew, D. (2013). Parent-child relationship quality directly and indirectly influences hooking up behaviour reported in young adulthood through alcohol us in adolescence. Arch Sex Behaviour, 42, 1463-1472.Karriker-Jaffe, K. J., Foshee, V. A., Ennett, S. T., & Suchindran, C., (2008). The development of aggression during adolescence: Sex differences intrajectories of physical and social aggression among youth in rural areas. Journal Abnormal.Child Psycholology, 36, 1227–1236.Kementerian Dalam Negeri (Kemendagri). (2014). Kode dan data wilayah administrasi pemerintahan. Jakarta: Ditjen Kependudukan dan Catatan Sipil Kemendagri Per Semester I.Klahr, A.M., McGue, M., Lacono, W.G., & Burt, S.A. (2011). The association between parent–child conflict and adolescent conduct problems over time: Results from a longitudinal adoption study. Journal Abnormal Psychology, 120, 46–56.Masten, A. S. (2001) Resiliensi process in development. American Psichological Association, 56(3), 227-228.Mathijssen, J. P. J., Janssen, M. M., Bon-Martens, M., Oers, H. A., Boer, A. D., & Garretsen, H. F. (2014). Alcohol segment-specific associations between the quality of the parent-child relationship and adolescent alcohol use. Journal of Public Health, 872, 1471-2458.Leather, N. C. (2009). Risk-taking behaviour in adolescence: A literature review. Journal of Child Health Care,13(3), 295–304. Oni, A. A. (2010). Peer group pressure as a determinant of adolescent social adjustment in Nigerian schools. Asian Pasific Journal of Educators and Education, 25, 189-202.Peacock, A., & Bruno, R. (2015). Young adults who mix alcohol with energy drink: Typology of risk taking behaviour. Addictive Behaviours, 45, 252-258.Qu, Y., Fuligni, A. J., Galvan, A., & Telzer, E. H. (2015). Buffering effect of positive parent–child relationships on adolescent risk taking: A longitudinal neuro imaging investigation. Developmental Cognitive Neuroscience, 15, 26–34.Ritcher. (2010). Risk behavior in adolescence, patterns, determinants, and consequences. Germany: Springer Fachmedien.Sales, J. M., & Irwin, C. E., Jr. (2009). Theories of adolescent risk-taking: A biopsychosocial model. In R. DiClemente & R. Crosby (Eds.), Adolescent health:Understanding and preventing risk behaviors andadverse health outcomes (pp. 31–50). San Francisco, CA: Jossey-Bass.Santrock, J. W. (2003). Adolescene: Perkembangan remaja. Jakarta: Erlangga.Savitri, A. R. (2015, Desember 11). Inilah organisasi paling nge-hits di Yogyakarta. Youth Forum. Retrieved from http://www.duniaremaja. jogjaprov.go.id/detilberita/14/1/Inilah-Organisasi-Paling-Nge-Hits-di-Yogyakarta,-YouthForum-DIYSkaar, N. R. (2009). Development of the adolescent exploratory and health risk behaviour rating scale(Unpublished dissertation). University of Minnesota, United Stated.Sofronoff, Dalgliesh, & Kosky. (2004). Out of options, a cognitive model of adolescent suicide and risk-taking. USA: Cambridge University Press.Stattin, H., & Kerr, M. (2000). Parental monitoring: A reinterpretation. Child Developmental, 71, 1072-1085.Survei Demografi dan Kesehatan Indonesia. (2013). Kesehatan reproduksi remaja. Badan Pusat Statistik. Jakarta: Indonesia.Tsai, K. M. (2013). Continuity and discontinuity in perceptions of family relationship from adolescence to young adulthood. Journal of Child Development, 84(2), 471-484.Turley, R. N. L., Desmond, M., & Bruch, S. K. (2010). Unanticipated educational consequences of a positive parent-child relationship. Journal of Marriage and Family, 72(5), 1377-1390.
41
Lindley, Jill, Yahse Edah, Olga Lomovskaya, Mariana Castanheira, and Mariana Castanheira. "1053. The β-Lactamase Inhibitor QPX7728 Restores the Activity of β-Lactam Agents against Contemporary Extended-Spectrum β-lactamase (ESBL)-Producing and Carbapenem-Resistant Enterobacterales (CRE) Isolates, Including Isolates Producing Metallo-β-lactamases." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S617—S618. http://dx.doi.org/10.1093/ofid/ofab466.1247.
Full textAbstract:
Abstract Background The β-lactam (BL)/ β-lactamase inhibitor (BLI) combinations approved in the last 10 years are active against most ESBL-producing Enterobacterales (ENT) and CRE isolates, but have limited activity against metallo-β-lactamase (MBL)-producing ENT. We evaluated the activity of QPX7728 (QPX), a novel BLI with intravenous (IV) and oral availability, in combination with BL agents. We tested ENT isolates carrying the most common BL genes such as blaCTX-M, transferable AmpCs, oxacillinases, MBLs, and serine carbapenemases. Methods A total of 1,027 ENT isolates were susceptibility (S) tested by reference broth microdilution against aztreonam (ATM), cefepime (FEP), cefdinir (CDR), ceftibuten (CTB), ceftolozane (CT) and piperacillin (PT) with fixed 4 mg/L of tazobactam, biapenem (BPM), meropenem (MER), and tebipenem (TEB) combined with QPX at fixed 4 and 8 mg/L. All isolates were genetically characterized using whole genome sequencing and included 520 ESBL-producers and 507 CRE with 168 producing MBLs. Results BL agents tested alone had limited activity against this challenge set of isolates (MIC90, ≥32 mg/L); however, MIC90 values decreased ≥32-fold with the addition of QPX at the highest concentration tested (Table). Oral agents, CTB,CDR and TEB were tested with QPX at a fixed 4 mg/L and showed a 32- to 128-fold increase in potency (MIC90, 0.5-4 mg/L). ATM and FEP were tested with QPX at a fixed 4 and 8 mg/L and displayed MIC90 values ranging from 0.12-0.5 mg/L. ATM and FEP, tested with 8 mg/L of QPX, inhibited 99.8% of isolates at the breakpoint for the BL agent alone. BLI inhibitor combinations PT and CT displayed MIC90 values of 2 and 4 mg/L with the addition of 8 mg/L QPX. MER with QPX at a fixed 4 mg/L and 8 mg/L inhibited 99.8% and 100% of isolates, respectively. Conclusion The activity of all BLs evaluated was restored when combined with QPX tested against this challenging collection of 1,027 ENT isolates displaying various resistance mechanisms, including difficult to treat CRE isolates and MBL producers. Further development of QPX with various orally- and IV-available BL agents appears warranted. Disclosures Jill Lindley, Bravos Biosciences (Research Grant or Support)ContraFect Corporation (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support) Yahse Edah, AS, Qpex (Research Grant or Support) Olga Lomovskaya, PhD, Qpex Biopharma (Employee) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors (Individual(s) Involved: Self): Research Grant or Support; Allergan (Individual(s) Involved: Self): Research Grant or Support; Amicrobe, Inc (Individual(s) Involved: Self): Research Grant or Support; Amplyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contrafect (Individual(s) Involved: Self): Research Grant or Support; Cormedix (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; Curza (Individual(s) Involved: Self): Research Grant or Support; CXC7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Fox Chase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardian Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; IHMA (Individual(s) Involved: Self): Research Grant or Support; Janssen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosceinces (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Luminex (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; Nabriva (Individual(s) Involved: Self): Research Grant or Support; National Institutes of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEX Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RIHML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; Salvat (Individual(s) Involved: Self): Research Grant or Support; Scynexis (Individual(s) Involved: Self): Research Grant or Support; SeLux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher Scientific (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Southwestern (Individual(s) Involved: Self): Research Grant or Support; VenatoRx (Individual(s) Involved: Self): Research Grant or Support; Viosera Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support
42
Shortridge, Dee, Jennifer M. Streit, Leonard R. Duncan, Mariana Castanheira, and Mariana Castanheira. "1308. Activity of Cefiderocol and Comparators against Gram-negative Isolates from US Patients Hospitalized with Pneumonia." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S742—S743. http://dx.doi.org/10.1093/ofid/ofab466.1500.
Full textAbstract:
Abstract Background Cefiderocol (CFDC) is a novel siderophore-conjugated cephalosporin with broad activity against Gram-negative (GN) bacteria, including carbapenem-resistant isolates, and non-fermentative organisms. CFDC is approved by the FDA for complicated urinary tract infection (cUTI), hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia. In this study, we analyzed the susceptibility of CFDC and comparators against aerobic nonfastidious GN isolates collected from US patients hospitalized with pneumonia (PHP) in 2020 as a part of the SENTRY Antimicrobial Surveillance Program. Methods A total of 1,877 Gram-negative isolates were consecutively collected from PHP in 27 US hospitals during 2020. Susceptibility (S) testing was performed using the CLSI broth microdilution method. CFDC was tested in iron-depleted Mueller-Hinton broth. CLSI or FDA (2021) breakpoints were used. Both CLSI and FDA (2021) interpretations are shown in the table. Carbapenem-resistant Enterobacterales (CRE, nonsusceptible to imipenem and/or meropenem) and extensively drug resistant (XDR, susceptible to ≤ 2 drug classes) phenotype isolates were analyzed. Results The most common GN organism isolated from PHP was Pseudomonas aeruginosa (PSA, n=570), followed by Klebsiella pneumoniae (n=239). The %S and MIC50/90 values of CFDC for both CLSI and FDA breakpoints and comparators are shown in the table for all organisms and resistant subsets. For Enterobacterales, all tested drugs had >99%S. The 18 CRE isolates had 94.4%S to CFDC and ceftazidime-avibactam. CFDC was the most active antimicrobial tested against PSA (99.3/98.4%S, CLSI/FDA) and XDR PSA (94.6/93.2%). CFDC had the highest %S against Acinetobacter baumannii-calcoaceticus species complex (ABC, 97.0/93.1%S, CLSI/FDA), XDR ABC (94.6/93.2%), and against Stenotrophomonas maltophilia (SM; 100.0/97.1%S, CLSI 2020/2022). Conclusion CFDC was highly active against US GN isolates from PHP, including CRE, XDR PSA and ABC, as well as SM. These in vitro results suggest that CFDC may be an important option for the treatment of PHP caused by GN organisms, particularly for pathogens which have few treatment options. Disclosures Dee Shortridge, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support) Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Leonard R. Duncan, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services (Research Grant or Support, Contract no. HHSO100201600002C)Shionogi (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors (Individual(s) Involved: Self): Research Grant or Support; Allergan (Individual(s) Involved: Self): Research Grant or Support; Amicrobe, Inc (Individual(s) Involved: Self): Research Grant or Support; Amplyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contrafect (Individual(s) Involved: Self): Research Grant or Support; Cormedix (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; Curza (Individual(s) Involved: Self): Research Grant or Support; CXC7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Fox Chase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardian Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; IHMA (Individual(s) Involved: Self): Research Grant or Support; Janssen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosceinces (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Luminex (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; Nabriva (Individual(s) Involved: Self): Research Grant or Support; National Institutes of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEX Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RIHML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; Salvat (Individual(s) Involved: Self): Research Grant or Support; Scynexis (Individual(s) Involved: Self): Research Grant or Support; SeLux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher Scientific (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Southwestern (Individual(s) Involved: Self): Research Grant or Support; VenatoRx (Individual(s) Involved: Self): Research Grant or Support; Viosera Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support
43
Shortridge, Dee, Jennifer M. Streit, Michael D. Huband, Mariana Castanheira, and Mariana Castanheira. "155. In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Community-Acquired Pneumonia and Community-Acquired Lower Respiratory Tract Infections: Results from the SENTRY Antimicrobial Surveillance Program (2014-2020)." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S93—S94. http://dx.doi.org/10.1093/ofid/ofab466.155.
Full textAbstract:
Abstract Background Delafloxacin (DLX) is a broad-spectrum fluoroquinolone antibacterial approved in the US for the treatment of community-acquired bacterial pneumonia (CABP). DLX is indicated to treat CABP caused by Streptococcus pneumoniae (SPN), Haemophilus influenzae (HI), Haemophilus parainfluenzae (HP), methicillin-susceptible Staphylococcus aureus (MSSA), Escherichia coli (EC), Klebsiella pneumoniae (KPN), Pseudomonas aeruginosa (PSA), Chlamydia pneumoniae, Mycoplasma pneumoniae and L. pneumophila. In this study, the in vitro susceptibilities of DLX and comparator quinolones were determined for clinical isolates from CAP and CA-lower respiratory tract infections (LRTIs). Methods CAP and CA-LRTI isolates were consecutively collected at 67 US medical centers participating in the SENTRY Surveillance Program during 2014-2020. Sites submitted 1 isolate per patient per infection episode. Isolate identification was determined at each site and confirmed using standard biochemical or molecular methods at JMI Laboratories. Susceptibility testing was performed according to CLSI broth microdilution methodology. CLSI (2021) interpretive criteria were applied, FDA criteria were used for DLX. Results The susceptibility results for DLX, levofloxacin (LEV), moxifloxacin (MOX), and ciprofloxacin (CIP) for the indicated species are shown in the table. As MOX does not have CLSI breakpoints for EC, KPN, or PSA, CIP was tested for those species instead. DLX had the highest percent susceptibility against MSSA (91.8%). SPN and HI were >97% susceptible, and HP was >91% for all 3 drugs. KPN susceptibility ranged from 86.4% for LEV to 76.9% for DLX. Susceptibilities for EC and PSA were similar for the 3 drugs, EC varied from 59.8% for LEV to 57.0% for DLX, and PSA varied from 71.6% for CIP to 64.0% to LEV. Conclusion DLX had good activity against recent CAP and CA-LRTI isolates from US hospitals. DLX had the highest susceptibility of the quinolones tested against MSSA. Quinolone-resistant SPN and HI were uncommon. These in vitro results suggest that DLX may be a useful therapeutic option for CABP caused by Gram-positive, Gram-negative and fastidious pathogens. Disclosures Dee Shortridge, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support) Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Michael D. Huband, BS, AbbVie (formerly Allergan) (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors (Individual(s) Involved: Self): Research Grant or Support; Allergan (Individual(s) Involved: Self): Research Grant or Support; Amicrobe, Inc (Individual(s) Involved: Self): Research Grant or Support; Amplyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contrafect (Individual(s) Involved: Self): Research Grant or Support; Cormedix (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; Curza (Individual(s) Involved: Self): Research Grant or Support; CXC7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Fox Chase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardian Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; IHMA (Individual(s) Involved: Self): Research Grant or Support; Janssen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosceinces (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Luminex (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; Nabriva (Individual(s) Involved: Self): Research Grant or Support; National Institutes of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEX Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RIHML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; Salvat (Individual(s) Involved: Self): Research Grant or Support; Scynexis (Individual(s) Involved: Self): Research Grant or Support; SeLux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher Scientific (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Southwestern (Individual(s) Involved: Self): Research Grant or Support; VenatoRx (Individual(s) Involved: Self): Research Grant or Support; Viosera Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support
44
Shortridge, Dee, S. J. Ryan Arends, Jennifer M. Streit, Mariana Castanheira, and Mariana Castanheira. "1280. Minocycline Activity Against Acinetobacter baumannii-calcoaceticus Species Complex, Burkholderia Cepacia Complex, and Stenotrophomonas maltophilia from US Hospitals." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S728. http://dx.doi.org/10.1093/ofid/ofab466.1472.
Full textAbstract:
Abstract Background Acinetobacter baumannii-calcoaceticus species complex (ACB), Burkholderia cepacia complex (BCC), and Stenotrophomonas maltophilia (SM) are opportunistic non-fermentative organisms that can cause serious hospital-acquired infections in immunocompromised patients. These pathogens are inherently resistant to several common drug classes and often acquire other resistance mechanisms, making them difficult to treat. In this study, we analyzed the susceptibility of contemporary ACB, BCC, and SM isolates to minocycline (MIN), ceftazidime (TAZ), levofloxacin (LEV), and trimethoprim-sulfamethoxazole (T/S). Isolates were collected as a part of the SENTRY Antimicrobial Surveillance Program from 2017-2020. Methods Isolates were collected from hospitalized patients in 33 US medical centers. Hospitals submitted 1 isolate per patient per infection episode that met local criteria for being the likely causative pathogen. Identification was performed by the submitting laboratory and confirmed by JMI Laboratories with matrix-assisted laser desorption ionization-time of flight mass spectrometry or other standard methods as required. Isolates were tested for susceptibility (S) to MIN and comparators using the CLSI broth microdilution method. All infection types were included in the analysis. CLSI (2021) breakpoints were applied. Results The most common infection that ACB, BCC, and SM were isolated from was pneumonia in hospitalized patients (57.9%, 81.1%, and 73.9%, respectively) followed by skin and skin structure infections for ACB (21.5%) or bloodstream infections for BCC (13.5%) and SM (11.8%). The %S and MIC50/90 values of the 4 drugs tested against the organisms in this study are shown in the table. MIN had the highest %S for ACB (85.9%S) and SM (99.3%S). TAZ had the highest %S (87.8%S) for BCC, while MIN and T/S had similar %S at 82.4%S and 83.8%S, respectively. Conclusion MIN had >82% S for the pathogens in this study, which have limited therapeutic alternatives. Options are particularly limited for BCC and SM, which have only 7 drugs with CLSI breakpoints. These in vitro data suggest that MIN remains a useful treatment option for infections caused by ACB, BCC, or SM. Disclosures Dee Shortridge, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support) S J Ryan Arends, PhD, AbbVie (formerly Allergan) (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors (Individual(s) Involved: Self): Research Grant or Support; Allergan (Individual(s) Involved: Self): Research Grant or Support; Amicrobe, Inc (Individual(s) Involved: Self): Research Grant or Support; Amplyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contrafect (Individual(s) Involved: Self): Research Grant or Support; Cormedix (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; Curza (Individual(s) Involved: Self): Research Grant or Support; CXC7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Fox Chase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardian Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; IHMA (Individual(s) Involved: Self): Research Grant or Support; Janssen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosceinces (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Luminex (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; Nabriva (Individual(s) Involved: Self): Research Grant or Support; National Institutes of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEX Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RIHML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; Salvat (Individual(s) Involved: Self): Research Grant or Support; Scynexis (Individual(s) Involved: Self): Research Grant or Support; SeLux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher Scientific (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Southwestern (Individual(s) Involved: Self): Research Grant or Support; VenatoRx (Individual(s) Involved: Self): Research Grant or Support; Viosera Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support
45
Carvalhaes, Cecilia G., Jaideep Gogtay, Cheung Yee, Sandhya Das, Mariana Castanheira, Mariana Castanheira, Rodrigo E. Mendes, and Helio S. Sader. "1229. Antimicrobial Activity of Plazomicin against Multidrug-resistant Enterobacterales: Results from 3 Years of Surveillance in Hospitals in the United States (2018–2020)." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S703—S704. http://dx.doi.org/10.1093/ofid/ofab466.1421.
Full textAbstract:
Abstract Background Multidrug-resistant (MDR) Enterobacterales isolates have increased and remain elevated in many US hospitals. Aminoglycoside (AMG) resistance often co-exist with resistance to other classes of antibiotics. A newer aminoglycoside, plazomicin, was evaluated against a large collection of MDR Enterobacterales clinical isolates from US hospitals. Methods A total of 456 MDR isolates (1/patient) were collected from 32 US medical centers located in 23 states in 2018-2020 and susceptibility tested by broth microdilution method at a central laboratory. MDR was defined as nonsusceptible (NS) to ≥3 antimicrobial classes and extensively drug-resistant (XDR) as susceptible (S) to ≤2 classes. Isolates resistant to aminoglycosides and/or broad-spectrum cephalosporins were screened for aminoglycoside-modifying enzymes (AME), 16S rRNA methyltransferases, and β-lactamases by whole genome sequencing. Results PLZ inhibited 93.0% of the MDR isolates (MIC50/90, 0.5/1 mg/L) and showed MIC values 8- to 16-fold lower than amikacin (AMK; MIC50/90, 4/16 mg/L; 93.2%S; Table). AMK S rates were 84.6% and 69.3% when EUCAST (≤8 mg/L) and USCAST (≤4 mg/L) breakpoints were applied, respectively. Among agents from other classes, S rates were 85.5% for meropenem, 88.4% for tigecycline, 49.3% for piperacillin-tazobactam, and 17.8% for cefepime; only the carbapenems and tigecycline were active against >50% of MDR isolates. PLZ retained activity against isolates NS to AMK (83.9%S), gentamicin (GEN; 89.3%S), and/or tobramycin (TOB; 92.4%S). PLZ showed markedly higher S rates than AMK against XDR (93.3% vs. 71.7%), AME producers (97.6% vs. 90.2%), and carbapenemase (CPE) producers (98.1% vs. 67.9%). PLZ was active against 99.0% of ESBL producers, while AMK S rates were 96.2%/87.0% as per the US FDA/EUCAST against these organisms. PLZ and AMK showed similar S rates when tested against GEN-NS isolates. GEN and TOB exhibited limited activity against MDR and all resistant subsets. Conclusion Despite co-resistance to aminoglycosides and other classes of antibiotics observed with MDR Enterobacterales isolates, PLZ remained highly active against these isolates including AME-, ESBL-, and/or CPE-producers that cause infections in US hospitals. Table Disclosures Cecilia G. Carvalhaes, MD, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support) Jaideep Gogtay, n/a, Cipla Therapeutics (Employee)Cipla USA Inc. (Employee) Cheung Yee, MSc, PhD, Cipla Therapeutics (Employee) Sandhya Das, n/a, Cipla Therapeutics (Employee) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors (Individual(s) Involved: Self): Research Grant or Support; Allergan (Individual(s) Involved: Self): Research Grant or Support; Amicrobe, Inc (Individual(s) Involved: Self): Research Grant or Support; Amplyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contrafect (Individual(s) Involved: Self): Research Grant or Support; Cormedix (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; Curza (Individual(s) Involved: Self): Research Grant or Support; CXC7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Fox Chase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardian Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; IHMA (Individual(s) Involved: Self): Research Grant or Support; Janssen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosceinces (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Luminex (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; Nabriva (Individual(s) Involved: Self): Research Grant or Support; National Institutes of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEX Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RIHML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; Salvat (Individual(s) Involved: Self): Research Grant or Support; Scynexis (Individual(s) Involved: Self): Research Grant or Support; SeLux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher Scientific (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Southwestern (Individual(s) Involved: Self): Research Grant or Support; VenatoRx (Individual(s) Involved: Self): Research Grant or Support; Viosera Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services (Research Grant or Support, Contract no. HHSO100201600002C)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)
46
Castanheira, Mariana, Mariana Castanheira, Rodrigo E. Mendes, and Helio S. Sader. "202. Comparative Activity of Ceftazidime-Avibactam, Imipenem-Relebactam and Meropenem-Vaborbactam Tested Against Carbapenem-Nonsusceptible Enterobacterales that Are Carbapenemase-Negative." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S123—S124. http://dx.doi.org/10.1093/ofid/ofab466.202.
Full textAbstract:
Abstract Background Most carbapenem-nonsusceptible Enterobacterales (CNSE) produce carbapenemases, but some isolates do not carry these enzymes. Ceftazidime-avibactam (CAZ-AVI), meropenem-vaborbactam (MBV), and imipenem-relebactam (IMR) have activity against CNSE isolates producing serine-carbapenemases, but these agents might have variable activity against isolates that do not produce these enzymes. We evaluated the activity of these agents against a collection of 170 carbapenemase-negative CNSE collected during 5 years in US hospitals. Methods Enterobacterales isolates (n=47,858) collected in US hospitals from 2016-2020 were susceptibility (S) tested by reference broth microdilution methods. Results were interpreted using CLSI 2020 breakpoints. CNSE displayed nonsusceptible (NS) MICs for imipenem or meropenem. CNSE isolates were screened for carbapenemase genes using whole genome sequencing. Results Among 685 (1.4% of the isolates) CNSE, 170 (24.8% of the CNSE) isolates did not produce carbapenemases. Most of these isolates were K. aerogenes (n=42), K. pneumoniae (32), and E. cloacae (32), but 13 other species also were carbapenemase negative. CAZ-AVI inhibited all carbapenemase-negative CNSE isolates (Figure). MBV and IMR inhibited 97.6% and 92.3% of the isolates. Amikacin (AMK) and tigecycline (TIG) inhibited 97.1% and 93.5%, while levofloxacin and meropenem (MEM) inhibited 63.5% and 64.7%. A total of 141 (82.9%) isolates were nonsusceptible (NS) to imipenem. When MEM NS isolates (n=60) were analysed separately, the S rates were lower for all agents except CAZ-AVI. CAZ-AVI inhibited all MEM NS carbapenemase-negative CNSE isolates. MBV and IMR inhibited 93.1% and 89.7% of these isolates, respectively. AMK and TIG inhibited 93.3% and 88.3%, respectively. Only 8.3% of the isolates were resistant to colistin. Conclusion CAZ-AVI displayed good activity against carbapenemase-negative CNSE isolates, including all MEM NS that displayed greater resistance rates against all comparator agents. High-risk patients with infections caused by CNSE have an increased mortality rate compared to isolates susceptible to these agents. Implementation of appropriate therapy for these isolates is critical. Disclosures Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors (Individual(s) Involved: Self): Research Grant or Support; Allergan (Individual(s) Involved: Self): Research Grant or Support; Amicrobe, Inc (Individual(s) Involved: Self): Research Grant or Support; Amplyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contrafect (Individual(s) Involved: Self): Research Grant or Support; Cormedix (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; Curza (Individual(s) Involved: Self): Research Grant or Support; CXC7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Fox Chase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardian Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; IHMA (Individual(s) Involved: Self): Research Grant or Support; Janssen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosceinces (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Luminex (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; Nabriva (Individual(s) Involved: Self): Research Grant or Support; National Institutes of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEX Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RIHML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; Salvat (Individual(s) Involved: Self): Research Grant or Support; Scynexis (Individual(s) Involved: Self): Research Grant or Support; SeLux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher Scientific (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Southwestern (Individual(s) Involved: Self): Research Grant or Support; VenatoRx (Individual(s) Involved: Self): Research Grant or Support; Viosera Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services (Research Grant or Support, Contract no. HHSO100201600002C)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)
47
Sader, Helio S., Leonard R. Duncan, Cheung Yee, Sandhya Das, Jaideep Gogtay, Mariana Castanheira, and Mariana Castanheira. "1267. Five-Year Trend on the Susceptibility of Enterobacterales to Plazomicin and Other Aminoglycosides in Hospitals in the United States (2016–2020)." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S721—S722. http://dx.doi.org/10.1093/ofid/ofab466.1459.
Full textAbstract:
Abstract Background Plazomicin (PLZ) is novel aminoglycoside (AMG) that was approved by the US FDA in June 2018 to treat complicated urinary tract infection (cUTI), including pyelonephritis. This agent is active against most isolates resistant to other AMGs. We evaluated PLZ activity against clinical isolates of Enterobacterales (ENT) from US hospitals. Methods 10,008 ENT isolates (1/patient) were collected from 35 US medical centers in 2016-2020 and susceptibility tested by the broth microdilution method at a central laboratory. PLZ breakpoints of ≤2/≥8 mg/L for susceptible [S]/resistant [R] (USFDA) were applied, and breakpoints established by the USFDA/CLSI, EUCAST and USCAST were applied to other AMGs for comparison. Isolates were mainly from cUTI (37.7%), bloodstream infection (24.9%), and pneumonia (20.3%). Results PLZ exhibited potent activity against ENT (MIC50/90, 0.5/1 mg/L), with S rates varying from 97.8% in 2016 to 95.8% in 2020 (96.8% overall). Against carbapenem-R ENT (CRE), S rates for PZL increased from 96.3% in 2016 to 100.0% in 2020 (Figure; 97.3% overall) and were markedly higher than amikacin (AMK; 75.2% overall), gentamicin (GEN; 48.7%), and tobramycin (TOB; 23.0%). The discrepancies between S rates for PLZ and other AMGs were greater when applying breakpoints generated using the same stringent contemporary methods applied to determine PLZ breakpoints. CRE S rates for AMK were 62.8% as per EUCAST and 52.2% as per USCAST. PLZ retained activity against GEN-non-S (NS; n=875; 90.6%S), TOB-NS (n=944; 92.7%S), and AMK-NS (n=60; 83.3%S) isolates. Among isolates from cUTI (n=3,774), 96.9% were PLZ-S, varying from 97.8% in 2017 to 95.8% in 2020. The ENT species most S to PLZ (lowest MIC values) were C. koseri (100.0%S), K. aerogenes (100.0%S), K. pneumoniae (99.8%S), and E. cloacae (99.7%S), which had MIC50/90 values of 0.25/0.5 mg/L, followed by K. oxytoca (MIC50/90, 0.5/0.5 mg/L; 99.9%S), E. coli (MIC50/90, 0.5/1 mg/L; 99.6%S), and C. freundii (MIC50/90, 0.5/1 mg/L; 100.0%S). Conclusion PLZ demonstrated potent activity against a large collection of contemporary ENT isolates from US hospitals with 4-fold lower MIC values than AMK. PLZ was markedly more active than AMK, GEN, or TOB against CRE and retained good activity against isolates NS to these AMGs. Disclosures Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services (Research Grant or Support, Contract no. HHSO100201600002C)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Leonard R. Duncan, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services (Research Grant or Support, Contract no. HHSO100201600002C)Shionogi (Research Grant or Support) Cheung Yee, MSc, PhD, Cipla Therapeutics (Employee) Sandhya Das, n/a, Cipla Therapeutics (Employee) Jaideep Gogtay, n/a, Cipla Therapeutics (Employee)Cipla USA Inc. (Employee) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors (Individual(s) Involved: Self): Research Grant or Support; Allergan (Individual(s) Involved: Self): Research Grant or Support; Amicrobe, Inc (Individual(s) Involved: Self): Research Grant or Support; Amplyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contrafect (Individual(s) Involved: Self): Research Grant or Support; Cormedix (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; Curza (Individual(s) Involved: Self): Research Grant or Support; CXC7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Fox Chase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardian Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; IHMA (Individual(s) Involved: Self): Research Grant or Support; Janssen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosceinces (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Luminex (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; Nabriva (Individual(s) Involved: Self): Research Grant or Support; National Institutes of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEX Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RIHML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; Salvat (Individual(s) Involved: Self): Research Grant or Support; Scynexis (Individual(s) Involved: Self): Research Grant or Support; SeLux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher Scientific (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Southwestern (Individual(s) Involved: Self): Research Grant or Support; VenatoRx (Individual(s) Involved: Self): Research Grant or Support; Viosera Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support
48
Mendes, Rodrigo E., Timothy B. Doyle, Ian A. Critchley, Nicole Cotroneo, Jennifer M. Streit, Mariana Castanheira, and Mariana Castanheira. "1254. Molecular Epidemiology of Escherichia coli Causing Urinary Tract Infections in United States and in vitro Activity of Tebipenem, Including Against Strain Lineage and Resistant subsets (2018-2020)." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S715—S716. http://dx.doi.org/10.1093/ofid/ofab466.1446.
Full textAbstract:
Abstract Background Tebipenem (TBP) is an oral carbapenem in clinical development for treating complicated urinary tract infections (UTIs), including pyelonephritis. This study investigates the epidemiology of E. coli (EC) causing UTI in U.S. patients and the activity of TBP and comparators against various subsets. Methods A total of 2,395 EC recovered from urine samples during the 2018-2020 STEWARD Surveillance Program were included. Isolates were collected from medical centers in all 9 US Census Regions and centrally tested by reference broth microdilution method. MIC interpretation was based on CLSI criteria. Isolates that met MIC criteria were subjected to genome sequencing, followed by screening of extended-spectrum β-lactamase (ESBL) genes and epidemiology typing (MLST). Results A total of 16.1%, 15.4% and 14.6% of EC met the ESBL screening criteria in 2018, 2019 and 2020, respectively. 269/360 (74.7%) carried blaCTX-M and 2/360 (0.6%) had blaSHV-12. blaCMY (33/360; 9.2%) was the most common cephalosporinase, followed by blaDHA (7/360; 1.9%). A CRE phenotype was noted in 1 isolate from New York, which carried blaKPC-2. Acquired genes were not detected in 56 strains. 50 ST types were noted in isolates that met the ESBL criteria screening, with the majority of isolates being ST131 (56.2%). 21 (6.7%) and 19 (6.0%) isolates belonged to ST38 and ST1193, respectively, followed by STs represented by 8 or less isolates. Among ST131, 56.5% carried blaCTX-M from group 1 and 35.6% had genes associated with group 9. Overall, TBP showed consistent MIC50 values throughout the subsets. ERT had activity (≥97.0% susceptible) against the various subsets; however, lower susceptibility rates (85.7-90.6%) were noted against isolates carrying plasmid AmpC. Other agents (ceftriaxone and cefazolin) had activity only against non-ESBL producers. Conclusion bla CTX-M comprised the majority of acquired genes detected among ESBL strains, which belonged mostly to ST131, emphasizing the expansion of this clone. TBP showed consistent activity against all subsets, regardless of resistance genotype or lineage. These data support the clinical development of TBP as a convenient oral treatment option for UTI caused by EC. Disclosures Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Timothy B. Doyle, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Ian A. Critchley, Ph.D., Spero Therapeutics (Employee, Shareholder) Nicole Cotroneo, Spero Therapeutics (Employee, Shareholder) Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors (Individual(s) Involved: Self): Research Grant or Support; Allergan (Individual(s) Involved: Self): Research Grant or Support; Amicrobe, Inc (Individual(s) Involved: Self): Research Grant or Support; Amplyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contrafect (Individual(s) Involved: Self): Research Grant or Support; Cormedix (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; Curza (Individual(s) Involved: Self): Research Grant or Support; CXC7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Fox Chase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardian Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; IHMA (Individual(s) Involved: Self): Research Grant or Support; Janssen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosceinces (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Luminex (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; Nabriva (Individual(s) Involved: Self): Research Grant or Support; National Institutes of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEX Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RIHML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; Salvat (Individual(s) Involved: Self): Research Grant or Support; Scynexis (Individual(s) Involved: Self): Research Grant or Support; SeLux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher Scientific (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Southwestern (Individual(s) Involved: Self): Research Grant or Support; VenatoRx (Individual(s) Involved: Self): Research Grant or Support; Viosera Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support
49
Mendes, Rodrigo E., Nicole Cotroneo, Ian A. Critchley, Brieanna Roth, S. J. Ryan Arends, Mariana Castanheira, and Mariana Castanheira. "1036. In Vitro Analysis of AmpC β-lactamase Induction by Tebipenem in Enterobacterales and Pseudomonas aeruginosa." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S608—S609. http://dx.doi.org/10.1093/ofid/ofab466.1230.
Full textAbstract:
Abstract Background Tebipenem (TBP) is an orally bioavailable carbapenem in clinical development in the US for treating complicated urinary tract infections and acute pyelonephritis. TBP possesses broad-spectrum activity against isolates producing penicillinases, narrow- and extended-spectrum β-lactamases, and AmpC β-lactamases. Exposure to β-lactams has been shown to increase AmpC production and impact susceptibility to β-lactams. This study assessed the induction properties of TBP over AmpC production in Gram-negative organisms. Methods Eight Enterobacterales species and 1 P. aeruginosa isolate were selected for AmpC induction experiments for TBP, imipenem, ertapenem (ETP), and ceftazidime. Induction experiments were performed at 0.25, 1, 4, and 16x MIC. AmpC induction was detected by measuring the intensity of nitrocefin hydrolysis compared to baseline. Isolates where a ≥4x induction of AmpC was detected were tested for susceptibility by the CLSI reference broth microdilution method. A second set of 36 Enterobacterales and 32 P. aeruginosa isolates with proven overexpression of AmpC by qRT-PCR were tested for susceptibility as well. Results In general, TBP and imipenem increased production of AmpC against all Enterobacterales, except for C. koseri and S. marcescens (Table). In contrast, ETP and ceftazidime did not seem to affect production of AmpC among the Enterobacterales species tested. All agents but ETP increased the production of AmpC in P. aeruginosa. Overall, an MIC increase (i.e., >4-fold) to various β-lactam agents was not observed when tested against isolates that showed an increased production of AmpC after drug exposure. When tested against the second set of Enterobacterales that over-produced AmpC, TBP (MIC50/90, 0.03/0.25 mg/L) inhibited all isolates at ≤1 mg/L. TBP showed MIC50 and MIC90 results of 4 and 4 mg/L, respectively, against P. aeruginosa isolates that over-produced AmpC. Conclusion Among Enterobacterales, exposure to either TBP or imipenem, but not ETP or ceftazidime, often resulted in increased measurement of AmpC production. However, increased production of AmpC did not translate into increased MIC values. Finally, TBP showed potent activity against Enterobacterales with confirmed overproduction of AmpC. Table Disclosures Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Nicole Cotroneo, Spero Therapeutics (Employee, Shareholder) Ian A. Critchley, Ph.D., Spero Therapeutics (Employee, Shareholder) Brieanna Roth, n/a, Spero Therapeutics (Research Grant or Support) S J Ryan Arends, PhD, AbbVie (formerly Allergan) (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors (Individual(s) Involved: Self): Research Grant or Support; Allergan (Individual(s) Involved: Self): Research Grant or Support; Amicrobe, Inc (Individual(s) Involved: Self): Research Grant or Support; Amplyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contrafect (Individual(s) Involved: Self): Research Grant or Support; Cormedix (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; Curza (Individual(s) Involved: Self): Research Grant or Support; CXC7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Fox Chase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardian Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; IHMA (Individual(s) Involved: Self): Research Grant or Support; Janssen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosceinces (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Luminex (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; Nabriva (Individual(s) Involved: Self): Research Grant or Support; National Institutes of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEX Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RIHML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; Salvat (Individual(s) Involved: Self): Research Grant or Support; Scynexis (Individual(s) Involved: Self): Research Grant or Support; SeLux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher Scientific (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Southwestern (Individual(s) Involved: Self): Research Grant or Support; VenatoRx (Individual(s) Involved: Self): Research Grant or Support; Viosera Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support
50
Castanheira, Mariana, Mariana Castanheira, Jennifer M. Streit, Helio S. Sader, and Dee Shortridge. "1238. Comparative Activity of Meropenem-Vaborbactam and Ceftazidime-Avibactam Against Multidrug-Resistant Enterobacter cloacae from Hospitals in Europe and United States." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S708—S709. http://dx.doi.org/10.1093/ofid/ofab466.1430.
Full textAbstract:
Abstract Background Enterobacter spp. are part of the ESKAPE pathogens that have been recognized as a threat to human health. Among this genus, E. cloacae species complex (ECL) is the most common species that causes human infections. ECL can develop resistance to ß-lactams and other antimicrobial classes due to alterations in gene regulatory pathways. We evaluated the activity of meropenem-vaborbactam, ceftazidime-avibactam, and comparator agents against 235 multidrug resistant (MDR) ECL isolates collected in Europe and the US during 2017-2019. Methods A total of 2,459 ECL clinical isolates were collected in 40 European and 33 US hospitals. Isolates were susceptibility tested by reference broth microdilution methods and results were interpreted using CLSI, EUCAST, and US FDA breakpoints. MDR was defined as resistant to 3 or more drug classes when applying the CLSI breakpoints. Results MDR ECL were observed among 9.6% of the overall isolates. The MDR rate in Europe (12.0%; 155/1,295) was considerably higher than in the US (6.9%; 80/1,164). Meropenem-vaborbactam inhibited 94.5% and 97.4% of the MDR ECL isolates applying CLSI and EUCAST breakpoints, respectively (Table). Meropenem inhibited 77.9%/85.5% of the isolates (CLSI/EUCAST breakpoints). Cefepime inhibited only 26.0%/16.2% of the MDR ECL isolates while piperacillin-tazobactam inhibited only 13.2%/6.4%. Ceftazidime-avibactam inhibited 93.6% of the MDR ECL isolates. Amikacin and tigecycline were the most active non-beta-lactam comparators, inhibiting 91.9% and 80.0% of these isolates using CLSI/US FDA breakpoints. A total of 93.1% of the isolates were intermediate to colistin applying CLSI breakpoints or susceptible using the EUCAST criteria. Meropenem-vaborbactam inhibited 73.5% and 87.8% of the MDR ECL isolates nonsusceptible to meropenem and cefepime, the main therapeutic option against ECL isolates. Ceftazidime-avibactam inhibited 73.5% of these isolates. Conclusion In a global surveillance, ECL is the second most common Enterobacterales species/species complex displaying MDR and carbapenem-resistance phenotypes, behind only Klebsiella pneumoniae. Meropenem-vaborbactam and ceftazidime-avibactam can be important options to treat infections caused by MDR ECL. Disclosures Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors (Individual(s) Involved: Self): Research Grant or Support; Allergan (Individual(s) Involved: Self): Research Grant or Support; Amicrobe, Inc (Individual(s) Involved: Self): Research Grant or Support; Amplyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contrafect (Individual(s) Involved: Self): Research Grant or Support; Cormedix (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; Curza (Individual(s) Involved: Self): Research Grant or Support; CXC7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Fox Chase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardian Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; IHMA (Individual(s) Involved: Self): Research Grant or Support; Janssen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosceinces (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Luminex (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; Nabriva (Individual(s) Involved: Self): Research Grant or Support; National Institutes of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEX Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RIHML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; Salvat (Individual(s) Involved: Self): Research Grant or Support; Scynexis (Individual(s) Involved: Self): Research Grant or Support; SeLux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher Scientific (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Southwestern (Individual(s) Involved: Self): Research Grant or Support; VenatoRx (Individual(s) Involved: Self): Research Grant or Support; Viosera Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services (Research Grant or Support, Contract no. HHSO100201600002C)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Dee Shortridge, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)